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Abstract 
The goal of this project was to study the difference between CWR22 prostate cancer 
xenografts with full androgen supply and after undergoing androgen deprivation and/or 
radiation therapy in immunedeficient mice by applying the non-invasive visualization 
methods dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-
weighted magnetic resonance imaging (DW-MRI). 
The experiment consisted of 32 male mice (25-35g, 6-8 weeks) with subcutaneously 
implanted CWR22 xenografts randomized into 4 groups of 8 mice: mice with control and 
irradiated CWR22 xenografts (group 1 and 2) and castrated mice with control and irradiated 
CWR22CA xenografts (group 3 and 4). Mice in group 1 and 2 were included in the 
experiment when the tumors‟ shortest diameter reached 8 mm. Mice in group 3 and 4 were 
castrated when the shortest tumor diameter was 13 mm, and inclusion was made when the 
shortest diameter reached 8 mm. The day of inclusion is called day 0. MRI was performed at 
day 0, day 1 (24 h) and day 9. The imaging protocol included sequences for DW-MRI, proton 
density images, dynamic T1-weighted images (DCE-MRI) and T2-weighted images. The 
transfer constant K
trans
, the extracellular extravascular volume, Ve, and the fraction of unfitted 
voxels were calculated from DCE-MRI data using Tofts and Kermode pharmacokinetic 
modeling. The mean apparent diffusion coefficient (ADC) was calculated from manually 
selected ROIs. Blood for PSA analysis was collected at all MRI days and at the last day of the 
experiment. The tumors in the irradiation groups were irradiated with a single fraction of 15 
Gy after the baseline MRI at day 0. In group 1 and 2 mice were sacrificed when 2 of tumor in 
the group reached 16 mm in biggest diameter, in group 3 and 4 - 30 days after initial MRI. 
Additionally 8 mice with identical weight as the other mice in the experiment were used to 
obtain vascular input functions (VIFs) by imaging the left ventricle. 
Exponentially growing CWR22 control tumors reached the endpoint of the experiment 
in 28 days, and irradiated CWR22 tumors in 69 days. The tumors in the CWR22 irradiated 
group showed a 31% volume decrease (p<0.01), before the regrowth started at day 41. At day 
23 the mean tumor volume of irradiated tumors was 5.3-fold less (p<0.01) than the mean 
tumor volume of CWR22 control tumors. In the CWR22 groups, tumor volume decreased 
during the whole experiment, reaching a 47% (p<0.01) and 70% (p<0.01) reduction at day 26 
for control and irradiation groups, respectively. The mice in the CWR22CA groups reached 
the experiment endpoint after 31±1 days after pre-treatment MRI. 
Total PSA concentration for the CWR22 control group increased at all consecutive 
measurements, while the CWR22 irradiated group showed a plateau between day 1 and 9. The 
mice bearing CWR22CA tumors showed reduced total PSA concentration at all measurement 
days compared to CWR22 groups. The decrease in total PSA concentration from day 9 to the 
end-point of the experiment was significant for both the control and the irradiation group 
(63% decrease, p < 0.01 and 94 % decrease, p = 0.01, respectively). There was a significant 
positive correlation (r=0.62, p<0.01) between tumor volume and total PSA blood 
concentration. The correlation was stronger for animals with CWR22 tumors (r = 0.73, p < 
0.01) than for animals with CWR22CA tumors (r = 0.27, p =0.02) 
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At day 0, K
trans
 of CWR22CA tumors was 47 % higher than of pre-radiation CWR22 
tumors (p = 0.01). Androgen-ablated CWR22CA tumors showed no significant changes in 
K
trans
 following radiation, whereas K
trans
 in fully androgen supplied tumors decreased from day 
0 to day 1 (p = 0.01), followed by an increase from day 1 to day 9 (p < 0.01). For the CWR22 
irradiated group, a 42% increase (p=0.03) of Ve was observed at day 9 compared to 
pretreatment values. For the CWR22 irradiated group, the fraction of unfitted voxels showed a 
211% increase (p=0.01) followed by a 57% decrease from day 1 to day 9 (p=0.03). A 
significant negative correlation between K
trans
 and the fraction of unfitted voxels for the 
CWR22 irradiated group (r = -0.69, p < 0.01), as well as using all tumors at all time points (r 
= -0.62, p < 0.01) was found  
Using a b-value of 300 s/m
2
, the CWR22 irradiated group showed a 39% (p<0.01) and 
63% (p<0.01) increase in ADC at day 9 compared to pretreatment value and value at day 1, 
respectively.  For b=600 s/m
2
, the increase was 35% (p=0.05) and 58% (p<0.01).For both b-
values at day 9, the ADC for the CWR22 irradiated group was 1.5-fold (p<0.01) and 1.6-fold 
(p<0.01) higher than for the CWR22 control group (b=300 s/m
2 
and b=600 s/m
2
 respectively). 
No significant changes in ADC values for CWR22CA control and irradiated groups were 
observed. 
In conclusion, changes in vascularization, vessel permeability, surface area and 
volume fraction of EES as a result of androgen deprivation and/or radiation therapy were 
observed. Increase in ADC for CWR22 xenografts after radiation treatment suggest structural 
changes at the last day of observation. As a result of androgen deprivation CWR22 xenografts 
developed a radiation resistant phenotype. The study suggests that serial monitoring of K
trans
 
could be a useful indicator of therapy responses in prostate cancer.  
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Nomenclature 
ADC - apparent diffusion coefficient 
ADC map – a map showing parametric images containing the ADC 
Adenocarcinoma – a cancer originating from glandular tissue 
AIF – Arterial Input Function 
Androgen – male sex hormones 
AR - Androgen Receptor 
Androgen deprivation therapy– a suppression of androgen production or utilizing of 
androgen by cells. 
AUGC - Area Under Gadolinium Contrast concentration curve 
Brachytherapy - delivery of radiation directly into the prostate 
Cryosurgery – a surgery, where tissue destruction is made by extreme low temperature 
CT – Computer Tomography 
CWR22 – an androgen-dependent human prostate cancer xenograft 
CWR22CA – an androgen-dependent human prostate cancer xenograft undergoing androgen 
deprivation therapy 
DCE-MRI – Dynamic Contrast Enhanced Magnetic Resonance Imaging  
DNA - Deoxyribonucleic Acid 
DW-MRI – Diffusion Weighted Magnetic Resonance Imaging 
EBRT - External Beam Radiotherapy 
EPI – Echo Planar Imaging 
EES - Extravascular Extracellular Space 
Fraction of unfitted voxels – fraction of volume element that failed the approximation with a 
model 
FID – Free Induction Decay 
FOV – Field Of View 
Gd-DTPA - Gadolinium DiethyleneTriaminePentaacetic Acid 
Gleason score – quantitative characteristic of the cancer tissue appearance under microscopy 
Gray – the SI unit of absorbed radiation dose due to ionizing radiation 
HIFU - High-Intensity Focused Ultrasound 
in vitro - the technique, where a procedure is performed outside a living organism. Cell 
experiments considered as in vitro 
in vivo – the technique, where a procedure is performed in a living organism 
Kep - a transport constant describing backflux from EES to plasma 
K
trans
 - a constant describing the transport of contrast agent from plasma into the EES 
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MVD - Microvessel Density  
MRI – Magnetic Resonance Imaging 
NMR - Nuclear Magnetic Resonance 
Nude mice - is a mouse with absence of thymus, resulting in an inhibited immune system due to a 
reduced number of T cells 
PSA – Prostate Specific Antigen 
Radical Prostatectomy - surgical elimination of prostate 
RF coil – a radiofrequent coil 
ROI – Region Of Interest 
SNR - Signal to Noise Ratio 
SSFSE - Single Shot Fast Spin Echo  
s.c. - subcutaneous 
TRUS - Transrectal Ultrasound 
VEGF - Vascular Endothelial Growth Factor  
Ve – fraction of extravascular extracellular space in tissue volume 
Xenograft – a transplanted cells, tissue or organs from one species to another, e.g. human tumor 
grown in mice 
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Chapter 1 
Introduction 
Prostate cancer is an adenocarcinoma of the prostate. The specific causes of its 
appearance remain unknown, but the risk factors are related to age, genetics and family 
history. Prostate cancer is responsible for 27% of new cases of cancer among men in Norway 
each year, being the most common type of cancer for men. In 2005, 3631 new cases were 
registered (Bray 2006). Norway is among the countries with the highest frequency and 
mortality rates of patients with prostate cancer. In some cases, especially in elderly patients, 
prostate cancer can be a moderate non-lethal disease that does not require treatment, but in 
other cases it is aggressive and lethal (Harris and Lohr 2002). The difficulty for clinicians is in 
deciding which men have fast-growing cancers that need advanced treatment and which have 
slow-growing cancers not requiring therapy. The clinical pattern of prostate cancer diagnosis 
has changed during the past few years. The proportion of men diagnosed at ages younger than 
70 years has increased, as has the proportion of moderately differentiated tumors. These 
trends are consistent with the effect of increased use of screening. Thus, it is important to 
have reliable methods, preferably non-invasive, to determine the disease aggressiveness. A 
large number of patients and few reliable markers that predicts treatment response is a 
recurring challenge in the clinic. 
Currently, treatment strategy for prostate cancer consists of, depending on disease 
stage and aggressivity, one or several of the following modalities: surgery (radical 
prostatectomy), radiation therapy (external beam radiotherapy or brachyterapy), hormone 
therapy or chemotherapy. In recent years some alternative treatment modalities like high-
intensity ultrasound or cryosurgery have been suggested for patients, but the popularity of 
these methods is low. About 1/3 of all patients diagnosed with prostate cancer are included 
into curative treatment in form of surgery and/or radiation therapy. One third of all patients 
diagnosed with prostate cancer will die of it (Bray 2006). Thus, it is important to find a 
marker and determine the mechanisms in prostate cancer that have consequences for 
treatment effect. This knowledge will make it possible to tailor-made the treatment plan for 
each patient and, eventually, increase the survival.  
The majority of primary diagnosed prostate cancer is androgen sensitive, requiring 
male sex hormones (androgens) to grow. By stopping the production of androgens or by 
blocking the androgen‟s influence on cancer cells, the disease progression can be slowed 
down and the tumor burden reduced. This is called androgen deprivation therapy and can be 
done by medicaments or surgical castration. Androgen deprivation therapy alone cannot cure 
prostate cancer. Radiation therapy is another important modality in prostate cancer 
management. Combination of androgen deprivation therapy with radiation therapy improves 
local control and disease-free survival for prostate cancer patients as compared to radiation 
therapy alone (Lee 2006, Widmark et al 2009). For successful application of radiation 
treatment a non-invasive technique for localization of treatment volumes (tumor volume and 
safety margins) and volumes of risk is needed. Use of MRI, CT and ultrasound in planning 
and administration of intensity-modulated radiation therapy and high dose-rate brachytherapy 
has become a clinical standard.  
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After a period of 2 to 5 years, elevation of prostate specific antigen (PSA) 
concentration in blood shows an initial stage of prostate cancer relapse (Bruchovsky et al 
1990, Trachtenberg 1987). The disease becomes hormone resistant and the cells will 
proliferate without androgen stimulation. The mechanisms involved in the early transition 
from androgen-dependent to androgen-independent prostate cancer are not fully understood. 
Today no curative treatment for patients with hormone resistant prostate cancer exists.  
Angiogenesis is very important in prostate cancer progression. The angiogenic process 
is a complex multistep sequence involving many growth factors (cytokines) and interactions 
between varieties of cell types (Alonzi et al 2007). Expression of angiogenic cytokines in 
prostate cancer can be induced as a response to hypoxic stress or hormonal stimulation. The 
angiogenic process in prostate cancer is highly dependent on the vascular endothelial growth 
factor (VEGF). Androgens seem to regulate VEGF expression in prostate cancer cells and 
benign prostatic tissues (Joseph et al 1997).  
One of the most promising non-invasive methods for imaging of viable tissue is 
functional magnetic resonance imaging (fMRI). In addition to obtain detailed anatomical 
images, MRI is increasingly being used to obtain biological information about vascularisation 
(dynamic contrast enhanced MRI) and molecular thermal motion (MR diffusion). These 
methods are promising in individualized, adaptive cancer treatment in the future.  
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) is a non-
invasive technique implementing a series of MR-images before, during and after intravenous 
injection of contrast agent. Contrast agents administrated intravenously can enhance MR 
image contrast by altering the T1, T2 and T2
*
 relaxation times. Paramagnetic ions with a 
number of unpaired electrons such as Gd
3+
 and Mn
2+ 
are used as contrast agents because of 
their high relaxivities. To reduce the toxicity of these ions for in vivo applications, they are 
chelated to special molecules. Gadolinium pentetate (Gd-DTPA), the currently most used 
MRI contrast agent, is a chelate composed of gadolinium ions and 
diethylenetriaminepentaacetic acid (DTPA). In tumor this low molecular weight contrast 
agent can leak through the capillary membrane into extravascular extracellular space EES, but it 
cannot penetrate into the cells. Signal enhancement is dependent on microvessel density, blood 
flow, vessel permeability and surface area. To monitor treatment response using DCE-MRI a 
quantitative pharmacokinetic Tofts and Kermode model can be applied (Tofts and Kermode 
1991). It is a two-compartment model with a constant describing the transport of contrast agent 
from plasma into EES, K
trans
, and a transport constant describing the backflux from EES to 
plasma, Kep. This constants relates to each other as Kep=K
trans
/Ve, where Ve is the fraction of 
extravascular extracellular space in tissue volume. Advantages of the Tofts and Kermode model is 
that it utilizes a bolus injection, a theoretical expression that only has concentration of contrast 
agent in tissue as an unknown, and fits well to gradient echo data from both human tumors 
and transplanted tumors (Tofts 1997). 
Diffusion weighted magnetic resonance imaging (DW-MRI) is a technique that 
visualizes water molecules motion in biological material. The diffusion signal is dependent on 
molecular viscosity and membrane permeability between intra- and extracellular 
compartments, active transport and flow, compartment shape and size (Moffat et al 2003, 
Kauppinen 2002). DW-MRI gives information about microstructure and can be used for 
detection of molecular and cellular treatment-related changes in tumor before the clinical 
parameters like reduction of tumor size can be observed. The majority of DW-MRI performed 
clinically is focusing on the extracellular water diffusion. In highly cellular tissues, such as 
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tumors, extracellular water diffusion is restricted, leading to a short diffusion path and a 
reduced apparent diffusion coefficient (ADC). Cystic or necrotic portions of tumors have few 
structural barriers present and have a high ADC. ADC maps, derived from diffusion-weighted 
imaging, can therefore provide a non-invasive measure of cellularity (Herneth et al 2003), 
being a promising tool in diagnosis, treatment planning and monitoring. 
One of the well established models in clinical experiments is the subcutaneous human 
xenograft (human tumor tissue implanted into an animal of other species) in immunodeficient 
mice (nude mice). It can be used to investigate biological and physiological properties of 
tumor tissue and to test treatments. The advantages of the model are easy establishment and 
manipulations of the tumor, positioning for imaging and obtaining of samples for histology. 
In addition, extrapolation of experimental data into clinical use is possible. 
The CWR22 xenograft is an androgen-dependent, human prostatic carcinoma 
xenograft established from a transurethral resection and grown subcutaneously in male 
athymic nude mice (Pretlow et al 1993). The CWR22 xenograft was taken from a stage D, 
Gleason score 9, prostatic carcinoma with osseous metastases and was the first serially 
growing primary prostatic carcinoma (Pretlow et al 1993). Upon androgen withdrawal, 
CWR22 PSA mRNA and protein decrease rapidly, cells undergo apoptosis and tumors regress 
in size (Wainstein et al 1994, Gregory et al 1995). After several months they recur in the 
absence of testicular androgens in a manner characteristic of human androgen-independent 
prostate cancers (Wainstein et al 1994, Gregory et al 1995). Thus, the CWR22 model allows 
the study of tumor behavior in both androgen-dependent and -independent states. In nude 
mice bearing CWR22 xenografts, Wainstein et al (Wainstein et al 1994) observed that serum 
PSA concentrations correlated with tumor size and that blood levels of PSA decreased after 
androgen withdrawal. 
The goal of this project was to study the difference between prostate cancer CWR22 
xenografts with normal androgen supply and undergoing androgen deprivation treatment in 
immunodeficient mice by applying noninvasive visualization methods, like DCE-MRI and 
DW-MRI. The specific aim was to determine if tumor vasculature represented by K
trans
, 
fraction of EES represented by Ve and tissue structure represented by ADC in prostate cancer 
xenografts with full androgen supply will change following androgen deprivation, and if it 
will affect the radiation response. It was investigated whether the functional MRI methods 
gave more information about treatment response than classical clinical marker for prostate 
cancer, like PSA and tumor volume.  
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Chapter 2 
Theoretical Background 
2.1. Cancer – biology and clinic 
2.1.1. Cancer as disease 
By definition of World Health Organization (WHO), cancer is a generic term for a 
large group of diseases that can affect any part of the body. One defining feature of cancer is 
the rapid creation of abnormal cells that grow beyond their usual boundaries, and which can 
invade adjoining normal tissue and spread to other organs through lymphatic channels or 
blood. This process is referred to as metastasis. Metastases are the major cause of death from 
cancer (WHO http://www.who.int/mediacentre/factsheets/fs297/en/). 
2.1.2. Cancer statistics 
Cancer is a major public health problem. Currently, one in 4 deaths in the United 
States is due to cancer (Jemal et al 2008). In Norway in 2006 it was 24488 incidences of 
cancer, of which 12903 occurred among men and 11585 among women. The four most 
common types are cancer of prostate, female breast, colon and lung, and they are responsible 
for half of the total cancer burden (12227 new cases). Cancer rates increase rapidly with age, 
and the vast majority in Norway, about 85% in men and 75% in women, occur in persons 
aged over 55 (Figure 2.1) (Bray 2006). 
 
Figure 2.1. Percentage distribution of cancer incidences by age in Norway in 2002-2006 
(Figure from Bray, 2006) 
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The relative impact of different types of cancer varies considerably with age. Figure 
2.2 shows an age-related distribution of cancer types in Norway from 2002 to 2006, with 
prostate cancer being the type of cancer with the highest incidence for men over 55 years. The 
2006 report from the Cancer Registry of Norway (Bray 2006) reveals a constant increase in 
new cases of prostate cancer. It also shows the rise in prostate cancer incidence since 1990, 
due to increased use of the prostate specific antigen (PSA) test, which became commercially 
available in 1989. A large proportion of the increasing burden can be attributed to 
demographic effects of population growth and ageing. 
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Table 2.2 Beginning, continues on next page 
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Figure 2.2. The most frequent incident cancers by age and sex in Norway in, 2002-2006 
(Figure from Bray, 2006)  
17 
 
In 2004, there were 10489 cancer deaths in Norway, 5589 in men and 4900 in women. 
Lung (1174 deaths), colorectal (806 deaths), prostate (1074 deaths) and female breast cancer 
(694 deaths) were responsible for about half of the total cancer mortality burden (Bray 2006). 
Lung cancer is the leading cause of cancer death in both men and women (Figure 2.3). 
 
Figure 2.3. Age-standardized mortality rate in Norway 2004 for selected cancers (Figure 
from Statistics Norway, Bray 2006) 
In men, there has been a steady increase in mortality rates of lung, prostate and 
colorectal cancer in Norway, since the 1970s. There is some evidence that resent mortality 
trends are more favorable for these cancer forms, with trends plateauing or beginning to 
decline (Bray 2006). In women, lung cancer mortality has been rising rapidly in the last 
decades relative to other cancers, but both breast and rectal cancer mortality rates have been 
decreasing. There are declines in mortality among younger population of several common 
cancers, including testicular cancer in men and leukemia in both sexes.  
Overall survival five years after a cancer diagnosis was estimated to 57% and 63% for 
men and women, respectively. The five-year survival probabilities in Norway are shown in 
Figure 2.4. Survival probabilities in men have doubled from the late 1950s in men (Figure 
2.5) and increased by 50% in women. Advances in cancer care, including the development of 
new treatment regimens and a multidisciplinary approach to cancer are contributors to this 
favorable trend. 
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Figure 2.4. Five-year relative survival probabilities in Norway for selected cancers, 
diagnoses 1997-2001 (Figure from Bray, 2006) 
 
 
Figure 2.5 Five-year relative survival probabilities in Norway for prostate cancer in men 
(Table from Bray 2006) 
2.2. Prostate cancer 
2.2.1. Causes 
Prostate cancer is an adenocarcinoma of prostate. The specific causes of prostate 
cancer remain unknown, but risk factors are related to age, genetics and family history. It is 
further reported that obesity, hormones, smoking, dietary factors, physical inactivity, 
occupation, vasectomy, genetic susceptibility and sexual factors are of importance (Hsing and 
Chokkalingam 2006).  
Several studies have shown a familial aggregation of prostate cancer (Steinberg et al 
1990, Cannon et al 1982, Grönberg et al 1996). A possible reason for this aggregation is 
19 
 
inheritance of genes causing prostate cancer, some of which show high penetrance, whereas 
other genes show polymorphism and low penetrance. An important breakthrough in prostate 
cancer research was the finding of fusion oncogenes (Tomlins et al 2005).  
The big difference in the incidence of prostate cancer between men in developed 
countries and in Asia is attributed to differences in lifestyles. Diet, pattern of sexual behavior, 
alcohol consumption and exposure to sun radiation are all important etiological factors 
(Kolonel et al 2004). The importance of nutritional factors for development of prostate cancer 
was noted in a Swedish study, in which both body-mass index and lean body mass were 
positively associated with the risk of prostate cancer, and were more strongly related to 
mortality than to incidence (Andersson et al 1997).  
The relation between physical exercise and prostate cancer has been studied without 
any firm conclusions (Damber et al 2008). Smoking probably results in a small increase in the 
risk (Plaskon et al 2003), whereas the relation with alcohol consumption is unknown. The 
strong antioxidants lycopenes, found in tomatoes, have been studied as possible protective 
agents for the development of prostate cancer (Etminan e al 2004). Some other micronutrients 
and vitamins, such as selenium, vitamin E, and vitamin D, have been associated with 
decreased risk for prostate cancer (Duffield et al 2003, Dagnelie et al 2004, Hartman et al 1998). 
2.2.2. Diagnosis 
Prostate cancer frequently grows slowly and does not cause a problem (Harris and 
Lohr 2002). The difficulty for clinicians is in deciding which men have fast-growing cancers 
that need treatment and which have slow-growing cancers not requiring therapy. The clinical 
pattern of prostate cancer has changed during the past few years (Mettlin et al 1996). The 
proportion of men diagnosed at ages younger than 70 years has increased, as has the 
proportion of moderately differentiated tumors. These trends are consistent with the effect of 
increased use of screening.  
Prostate cancer is diagnosed as localized or locally advanced. Diagnosis is based on 
examination of histopathological or cytological specimens from the gland (Hodge et al 1989). 
There is no accepted universal standard on how the samples should be taken (Aus et al 2005, 
Damber 2008). Staging of prostate cancer is mainly done on the basis of a digital rectal 
examination (Sobin and Wittekind 2002). Imaging modalities such as MRI and CT are 
currently not in wide-spread use in staging. Instead common clinical features, such as serum 
PSA concentration, tumour grade (Gleason score) of the biopsy, and stage from digital rectal 
examination, are used to establish the patient‟s risk of having microscopic extracapsular 
extension of the tumour (Partin et al 2001, Ohori et al 2004) The risk that a prostate cancer will 
have metastasized is closely associated with a high serum PSA concentration, a locally 
advanced prostate cancer, or a poorly differentiated tumor (Aus et al 2005). 
2.2.3. Prostate cancer angiogenesis 
Angiogenesis involves a cascade of events in which mature, resting host endothelial 
cells are stimulated to proliferate, degrade their basement membranes and to form new blood 
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vessels. The angiogenic process is a complex multistep sequence involving many growth 
factors (cytokines) and interactions between varieties of cell types (Alonzi et al 2007).  
Expression of angiogenic cytokines in prostate cancer can be induced as a response 
to hypoxic stress or hormonal stimulation, but can also result from activation of oncogenes. The 
angiogenic process in prostate cancer is highly dependent on vascular endothelial growth factor 
(VEGF). It has been shown that VEGF is produced in abundance by the prostatic secretory 
epithelium of normal, hyperplasic, and tumor containing glands (Jackson et al 1997). The 
physiological roles of VEGF in the prostate are poorly understood and targets may include 
cells other than the vascular endothelium. Androgens seem to regulate VEGF expression in 
prostate cancer cells and benign prostatic tissues (Joseph et al 1997).  
Increased microvessel density (MVD) is a potential prognostic factor that has been 
correlated with clinical and pathological stage, metastasis and histological grade in prostate 
cancer (Alonzi et al 2007). MVD has also been correlated with disease-specific survival and 
progression after treatment (Bettencourt et al 1998, Borre et al 1998, Hall et al 1994). MVD has 
not been shown to correlate consistently with outcome after radical prostatectomy (Rubin et al 
1999). 
2.2.4. Prognostic factors in prostate cancer 
The most commonly used markers are PSA, stage (extent of the cancer within and 
beyond the prostate) and histopathological evaluation the biopsy, including Gleason score 
(appearance of the cancer tissue in a biopsy specimen). 
Prostate specific antigen 
The most well-known prognostic marker that has been used to assess prognosis (as 
well as detection of early increase) is prostate specific antigen (PSA). PSA is a 30 to 33 kDa 
(237 amino residue in mature form) belonging to the human tissue kallikrein family. It is a 
serine protease with a chymotrypsin-like activity (Diamandis et al 2000). PSA is mainly 
produced by the glandular epithelium of the prostate and secreted into the seminal fluid at 
high concentrations. PSA blood concentration, as a result of leakage from prostate gland is 
one million times lower than in seminal plasma. The biological role of PSA is the proteolytic 
cleavage of the gel-forming proteins of the seminal fluid to promote the release and motility 
of the sperms. (Christensson et al 1990, Lilja et al 1989) In serum, PSA detectable by 
immunochemical methods is predominantly found as a complex with alpha-1-
antichymotrypsin (ACT). The free PSA represent about 5-30% of total immunoaccessible 
PSA in serum. A small amount of PSA complexed with other proteins is unavailable for 
immunochemical detection (Stenman et al 1991). 
A large number of men are being diagnosed with early-stage prostate cancer as a 
result of the increased use of PSA screening (Hughes et al 2005). There is no proof that PSA 
screening in USA is the reason for reduced mortality (Mettlin 2000, Potosky et al 2001). But, 
in one non-randomized screening project in Tyrol, Austria, an early detection program along 
with free availability of treatment showed a 20% risk reduction in mortality (Oberaigner et al 
2006).  
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Efforts have been made to find markers for early detection of prostate cancer, other 
than total serum PSA. In 2004, WHO arranged and international consultation to assess new 
markers (Stenman e al 2005). Despite total serum PSA still being the best marker, some 
urinary markers are being developed (Müller and Brenner 2006). 
The change over time in the serum concentrations of PSA (PSA doubling time or PSA 
velocity) has shown promise in prediction of outcome in patients with non-metastatic prostate 
cancer. A high pre-treatment PSA velocity has been associated with a high risk of disease 
recurrence and death from prostate cancer (D‟Amico et al 2005). A short PSA doubling time 
(i.e., a rapidly increasing PSA) after treatment is similarly associated with a poor prognosis 
(D‟Amico et al 2003, Maffezini et al 2007).  
Stage of disease 
The TNM system is a cancer staging system describing the extent of cancer in the 
body. The system has existed for more than 50 years (Gospodarowicz et al 2003), and was 
last updated in 2002 (Sobin and Wittekind 2002). TNM is an abbreviation for the extent of 
primary tumor (T), regional lymph node involvement (N) and spread of distant metastasis 
(M). The TNM staging aid medical staff to plan and evaluate the treatment, give an indication 
of prognosis, and enable clinics in different countries to collate information.  
Gleason score 
Gleason score of a prostate cancer reports the histological grade based upon 
microscopic appearance of a biopsy. From microscopic analysis a grade is assigned to the 
most common tumor pattern, and a second grade to the next common tumor pattern. The two 
grades are added to get the Gleason score. For example, a most common pattern graded as 2 
and a next common pattern graded as 3, reveals a Gleason score of 2 + 3 = 5. There are five 
possible tissue patterns (grades) with 1 being well differentiated (good prognosis) and 5 being 
poorly differentiated (poor prognosis). Thus, the Gleason score ranges from 2 to 10, with 10 
having the worst prognosis.  
Prognostic risk groups are now commonly used for patients with localized prostate 
cancer. These groups are usually based on pre-treatment variables such as TNM staging, 
serum PSA and biopsy grade or Gleason score. Table 2.1 shows a frequently used risk 
grouping (D‟Amico et al 1998, Thompson et al 2007), being used to establish post-treatment 
outcome after various curative treatments. These clinical variables are also used as validated 
risk calculators for which the 5-year outcome after treatments can be related to each patient‟s 
clinical characteristics (risk factors). 
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Table 2.1. Risk group classification for localized prostate cancer (Damber 2008) 
 Stage PSA Gleason score 
Low risk T1c to T2a 10 ng/ml or less 6 or less 
Intermediate risk T2b 10-20 ng/ml 7 
High risk T2c 20 ng/ml or greater 8 or greater 
 
2.2.5. Treatment of prostate cancer 
One third of those diagnosed with prostate cancer receives curative treatment 
including surgery and/or radiotherapy. Depending on the extension and aggressiveness of the 
disease the treatment is often extended with androgen deprivation and/or chemotherapy.  
2.2.5.1 Radical prostatectomy 
Radical perineal prostatectomy was first described in 1905 for the treatment of 
prostate cancer (Young 1905). In 1947, Millin described a retropubic approach for radical 
prostatectomy (Millin 1947). Both radical retropubic prostatectomy and radical perineal 
prostatectomy are associated with significant intraoperative and postoperative morbidity 
(Catalona and Scott 1986). Major complications included rectal injury, urethral injury, 
massive hemorrhage, pulmonary embolus, anastomotic leaks, lymphoceles, wound infections 
and incontinence. Virtually all men were rendered impotent. Therefore, many surgical 
candidates rather opted for radiation therapy because of the lower risk of erectile dysfunction. 
Robotic prostatectomy (RP) represents the latest advancement in surgical treatment of 
prostate cancer, being a minimally invasive surgical approach augmented by robotic 
technology. Schuessler and colleagues (Schuessler et al 1997) first performed laparoscopic 
radical prostatectomy in 1991, but they failed to demonstrate advantages versus open 
prostatectomy, and the procedure was abandoned. It was not until Guillonneau and Vallancien 
(Guillonneau and Vallancien 2000) and Abbou and colleagues (Abbou et al 2000) described 
and validated their techniques of laparoscopic prostatectomy that interest resurged in 
minimally invasive surgical treatment of prostate cancer. 
In a standard laparoscopic approach the instruments are controlled directly by the 
surgeon. The da Vinci
®
 robot (Intuitive Surgical, Sunnyvale, CA, USA) is a master-slave 
robotic system consisting of a free-standing robotic tower and a remote console in which the 
surgeon sits at and controls the robotic arms.  
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2.2.5.2 Radiation therapy 
(Based on Hall and Giacca (Hall and Giacca 2006) if else is not stated) 
Radiation therapy is the medical use of ionizing radiation to control malignant cells 
by altering the genetic code in the deoxyribonucleic acid (DNA). The cell cycle consists of 
four phases: G1 (first growth), S (synthesis), G2 (second growth) and M (mitosis, cell 
division). These phases are characterized by the structure of the chromosomes, which contain 
the genetic material. During the cell cycle each DNA molecule is replicated into two 
identical daughter DNA molecules. A higher fraction of malignant cells are cycling in the 
cell cycle compared to normal cells. Normal cells are generally in the resting phase (G0), 
continuously dividing to renew and replace cells. The damaging effect of radiation is most 
pronounced on proliferating cells and radiosensitvity describes how vulnerable a cell is to 
radiation damage. Cells in G0 are resistant to ionizing radiation and damages to the normal 
cells cause side effects.  
The therapeutic index is a comparison of the amount of radiation that causes the 
therapeutic effect to the amount that causes death. The balance of the therapeutic index is 
to ablate the tumor compartment with as limited impact as possible to the normal tissue. 
Therapies that either make the tumor more sensitive to radiation treatment or protect normal 
tissue from radiation therapy increase the therapeutic index.  
Radiation therapy delivers lethal or sublethal damage to the tumor. Sublethal 
damage can be intrinsically repaired by cells. Many cell systems have limited or no capacity to 
repair sublethal events, while other compartments have significant capability of sublethal 
repair. Prostate cancer is thought to have a significant capacity to repair sublethal events 
(FritzGerald et al 2008). There exist treatment protocols that modify the environment for repair 
and convert sublethal treatment into lethal treatment.  
The radiation response of normal cells and tumor cells are often described with a 
linear-quadratic cell survival model.  
2DDeS             (2.1) 
where S is the surviving fraction of cells, D is the radiation dose, and α and β is constants.  
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Figure 2.6. Cell survival curve representing the linear quadratic model. The dose at which 
the linear and quadratic components are equal is the ratio α/β (based on figure from Hall 
and Giacca (Hall and Giacca 2006)). 
In Figure 2.6 cell death as function of radiation dose is displayed on a semi-log Y-
axis with increasing dose on the X-axis since cell death is linear at low dose, and then 
exponential when the radiation dose increases. The α-component of cell death is the 
linear component and equals the logarithm of cell death per dose. The β component is the 
exponential phase and equals the logarithm of cell death per dose squared. The linear-
quadratic model describes variances in normal tissue and tumor response to radiation 
therapy. The ratio of α to β is often used to describe the radiation response of cells. Prostate 
cancer cells are thought to have a low α/β ratio, which means that they have a more protracted 
response to radiation therapy and require a high radiation dose over an extended period of 
time to achieve complete cell death. The linear-quadratic model permits evaluation of 
therapies both in vitro and in vivo and determine which phase of cell death therapies influence. 
Sequential or combination therapies may be used as to influence either the α (linear) and/or 
the β (exponential) component, or both components simultaneously. 
Certain tissues are extremely sensitive to radiation therapy and shows exponential 
cell death at low doses of radiation therapy. These have a high α-component in the cell-
survival model. Bone marrow progenitors including granulocytes, macrophages and sperm are 
examples of cells sensitive to radiation therapy as these enter exponential cell death at low 
doses of radiation therapy. Most epithelial normal tissue and tumors demonstrate the described 
two phases of cell death in response to radiation exposure (FritzGerald et al 2008). 
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2.2.5.3 External beam radiation therapy (EBRT)  
External beam radiotherapy (EBRT) uses high energy, typically 6 - 15 MeV, X-ray 
beams generated in a linear accelerator accurately targets the tumor volume. In the case of 
prostate cancer this will include the entire prostate gland with a margin and often also the 
seminal vesicles. The high energy X-rays cause cell death through DNA damage.  
EBRT is suitable for treatment of localised prostate cancer. It can be combined with 
androgen deprivation treatment or chemotherapy. For low risk disease the prostate alone will 
be treated, for intermediate and high risk nodal and seminal vesicle may be involved.  
CT based planning is used to reconstruct the treatment volume in three dimensions 
together with the organs at risk (rectum, bladder and femoral heads) before defining the beam 
sizes, angles and contributions using complex dosimetry algorithms. Three or four beams 
converging on the target are required for typical treatment of prostate cancer. The standard 
dose is 74 Gy, delivered in 2 Gy per fraction, daily Monday to Friday. In prostate cancer, the 
α/β ratio is estimated to be between 1.5 and 3.5, which is lower than other carcinoma types 
and favours hypo-fractionated regimes (dose larger than 2 Gy per fraction) (Moule and 
Hoskin 2009). 
2.2.5.4 Brachytherapy 
Brachytherapy is the delivery of radiation directly into the prostate. The greek word 
„brachy‟ means „close‟. Brachytherapy delivers a destructive dose to the tumor by implanting 
small radioactive seeds in the prostate, while minimizing rectal and urinary morbidity. Pasteau 
first reported insertion of a radium capsule per-urethra to irradiate prostate cancer in 1913 
(Pasteau and De l‟emploi 1919). The development of the transrectal ultrasound (TRUS) probe 
in Denmark in 1983 revolutionized brachytherapy. Using TRUS, accurate placement of the 
seeds in the prostate is achieved (Jamal et al 2008). 
Currently, brachytherapy uses iodine-125 or, less often, palladium-103, seeds (Grimm 
et al 1994). Iodine-125, having a half-life of 60 days and a mean energy of 26 KeV, has been 
available since the 1970s, and palladium-103, having a half-life of 17 days and a mean 
energy of 21 KeV, since the 1980s. The biochemical disease survival is not different between 
these two isotopes, but the toxity of palladium resolve more quickly (Wallner et al 2002). A 
novel isotope, Cesium-131, has a very short half-life of only 9.7 days and mean energy of 
29 KeV, delivering 90% of its therapeutic dose within 1 month. There is much interest in this 
isotope since the higher energy photon emission and shortened half-life may improve 
coverage of the prostate with fewer side effects (Jamal et al 2008).  
2.2.5.5. Hormone therapy 
Since the 1940s, androgen deprivation therapy has been a common treatment of 
prostate cancer, especially for metastatic stage of disease (Huggins and Hodges 1941). 
Testicular androgens are eliminated by surgical removal of the testicles, inhibition of pituitary 
secretion of luteinizing hormone or follicle-stimulating hormone by downregulation of 
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gonadotropin-releasing hormone (GnRH) receptor with agonist and antagonist, or 
administration of estrogens to reduce the secretion of GnRH by the hypothalamus. The 
availability of GnRH agonists and non-steroidal antiandrogens from 1980s made immediate 
hormonal intervention more attractive for patients and clinicians. Although endocrine therapy is 
palliative and not biologically curative, increased uptake of this treatment could contribute to 
decline mortality rates by delaying death from prostate cancer long enough for the patients to 
die of unrelated causes (Damber 2004). After a 2 to 5 years period after hormone deprivation 
hormone-dependent prostate cancer can change into a hormone-refractory type. Intermittent 
androgen suppression take into account that malignant prostate cancer cells remain in a 
hormone-dependent stage longer than under continuous treatment, thus leading to extended 
survival (Bruchovsky et al 1990, Trachtenberg 1987).  
2.2.5.6 Chemotherapy 
Multiple clinical trials have not yet established the benefit from the cytotoxic effect 
of chemotherapy in prostate cancer. Angiogenesis and cell-cycle kinetic therapies may both 
interact with radiation therapy, and may become important targets for improving cell death. 
Signaling-pathway inhibitors and cell-adhesion modulators may also become important 
supplements to radiation therapy as it is evidenced that radiation therapy has a relationship 
with these agents (FitzGerald 2004). 
2.2.5.7 Alternative treatment 
High-intensity focused ultrasound (HIFU) 
HIFU was first established in 1944 (Lynn and Putnam 1944), although it was 30 
years before its first use in clinical practice (Madersbacher et al 1995). It involves high-
intensity ultrasound waves focused on an area to cause tissue destruction due to the thermal 
effect and cavitation (Kennedy et al 2003). The thermal effect is due to absorption of 
ultrasound energy subsequently converted to heat, with temperatures of 70-100°C achieved 
within a few seconds. Cavitation occurs due to an interaction of ultrasound and 
microbubbles in the tissue, resulting in an oscillation of these bubbles and, thereby, tissue 
ablation. These processes result in coagulative necrosis of the tissue (Chapelon et al 1992). 
HIFU is used in treatment of organ-confined prostate cancer in patients not suitable for 
other treatments, either due to informed patient choice, comorbidity, or age (Rebillard et al 
2003). HIFU can be repeated without maximum dosage constraints. The most common side-
effects of HIFU include urinary retention and erectile dysfunction (Murat et al 2007).  
Cryosurgery 
In cryosurgery, cell death is obtained by direct cellular injury using cooled ultra-thin 
trans-perineal probes in the prostate (Jamal et al 2008). When temperature decreases, 
enzymatic paralysis results in cellular metabolic failure. Below -20°C, water in the 
intracellular environment crystallizes to ice, drawing fluid in from the extracellular 
environment and causing electrolyte imbalance. During the thawing phase, ice crystals 
coalesce and disrupt the cell membrane. Endothelial damage is the stimulus for platelet 
aggregation and microthrombs formation, leading to microcirculatory failure. The most 
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frequently observed complication associated with cryotherapy is erectile dysfunction, 
occurring in approximately 90% of preoperatively potent patients (Chin et al 2007). The 
main concern with cryotherapy is the lack of data from randomized controlled trials and 
long-term follow-up. 
2.2.6. Treatment strategy 
Localized prostate cancer 
Localized prostate cancer is the most commonly diagnosed stage. The choice of 
treatment (active monitoring, radical prostatectomy, or any type of radiotherapy) is based on 
tumor characteristics and the patient‟s life expectancy. It is recommended that men with a life 
expectancy of less than 10 years who have early-stage prostate cancer should be actively 
monitored as their first choice of treatment (Aus et al 2005) and that this approach is an option 
for all men in the low-risk group. Men with more poorly differentiated tumors and those with 
a long life expectancy are usually offered curative treatment. There is no cut-oﬀ limit for age 
when active therapy might be of value, thus clinicians have to define the individual patient‟s 
life expectancy. Even older men can benefit from curative treatment if they live long enough 
(Wong et al 2006). Of the treatments available, only radical prostatectomy has a survival 
advantage over watchful waiting. 
 
For patients receiving EBRT, the American Urological Association has issued 
guidelines on prostate cancer (Table 2.2). Whether EBRT needs to be combined with 
hormonal therapy when used in patients with clinically localized disease is not clear, but there 
seems to be some benefit for the combination (Dearnalay et al 2007). Brachytherapy using 
iridium-192 can also be used for localized disease, either as monotherapy or in combination 
with EBRT (Pickles and Pollack 2006).  
Table 2.2: American Urological Association‟s guidelines for treatment (Damber 2008) 
Risk grade of disease Therapy 
Low 
A radiation dose higher than 70 Gy might 
decrease the risk of PSA recurrence, but no 
difference in survival has been shown 
(Pollack et al 2002,  Zietman et al 2005) 
Intermediate 
Conventional-dose radiotherapy of 70 Gy or 
less with the use of neoadjuvant and 
concurrent hormonal therapy for 6 months 
might extend survival of patients. Higher 
radiation doses might reduce the risk of PSA 
recurrence, but no difference in survival has 
been shown (Pollack  et al 2002,  Zietman et 
al 2005) 
High 
A combination of long-term hormonal 
therapy (up to 3 years) might extend survival 
compared with EBRT alone ( D‟Amico et al 
2004, Bolle et al 2002) 
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Locally advanced prostate cancer 
Some patients with extracapsular extension of the tumor can still be offered treatment 
with curative intent. Radiotherapy has long been the standard option for these men. 
Effectiveness of radiotherapy can be improved by increasing dose escalation to more than 70 
Gy or combination of radiation with neoadjuvant- or adjuvant hormonal therapy. The use of 
short-term neoadjuvant hormonal therapy might result in improved biochemical control or 
local control and also in disease-specific survival. Longer periods of adjuvant hormonal 
therapy (up to 3 years after radiotherapy or indefinitely) will also result in an overall benefit 
in survival although benefit seems to be limited to patients with high Gleason scores (Aus et 
al 2005, Gerber et al 1997, Hsu et al 2007). Radical prostatectomy is in many cases not an 
option, because of the difficulties in obtaining free resection margins in patients who have 
extracapsular disease. Some patients with small tumors that extend outside the gland might 
still be candidates for surgery (Aus et al 2005, Hsu et al 2007). 
Second-line treatment after failed primary surgery or radiotherapy 
A rising serum PSA is often the first sign of treatment-failure, occurring months to 
years before clinical symptoms or radiographic signs of recurrent disease. The recurring 
disease is classified as local or systemic. Local failure is characterized by a late PSA increase 
(more than 12 months after primary treatment), a long PSA doubling time (a slow rise in PSA 
over time) and a not too aggressive disease at diagnosis. Systemic failure is expected for 
patients with early PSA increase, rapid PSA doubling time or adverse pathological change 
(Simmons et al 2007, Aus et al 2007). Most patients with local failure have a protracted 
course before clinical signs of disease recurrence become obvious, meaning that men with a 
remaining long life expectancy (5-10 years) can be offered a second curative treatment. After 
surgery such treatment is EBRT. Experimental therapies, such as HIFU and cryotherapy, are 
hampered by high complication rates and low chance of permanent success (Simmons et al 
2007, Aus et al 2007). For men with short life expectancy and men who received primary 
radiotherapy, the advice is watchful waiting with hormonal therapy if needed.  
Metastatic prostate cancer 
Androgen deprivation therapy is a primary treatment of metastatic prostate cancer 
(Huggins and Hodges 1941). Patients with extraprostatic growth, with or without lymph-node 
metastases, or distant metastases, are given endocrine therapy. 
Treatment of androgen-independent prostate cancer 
The renewed progression of metastatic androgen-independent prostate cancer is the final 
stage of the disease and constitutes a substantial threat of morbidity and mortality. Recently, two 
large clinical trials showed that docetaxel, alone or in combination with estramustine, improved 
the survival of men with hormone-refractory prostate cancer in comparison with mitoxantrone 
and corticosteroids (Petrylak et al 2005, Tannock et al 2004). Such biologically active drugs as 
angiogenesis and signal transduction inhibitors, vaccines and other immunomodulators have a 
potential to be a new treatment modality (Sowery et al 2007). Prostate cancer expresses unique 
targets that enable the development of specific vaccines to recognize the cancer cells without 
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affecting the benign tissue (Sowery et al 2007). 
2.3. Prostate cancer research models 
2.3.1. In vivo models 
In 1969, the first human tumor growing in an immunodeficient „„nude‟‟ (athymic) 
mouse was reported (Rygaard et al 1969). Since then, human tumor xenografts grown 
in nude mice (Giovanella et al 1972) or in mice with severe combined 
immunodeficiency (SCID) (Boxma et al 1983) have covered all of the major tumor types. 
In 1976, the Developmental Therapeutics Program at the National Cancer Institute (NCI) 
adopted 3 subcutaneously (s.c.) grown xenografts (colon, CX-1; breast, MX-1; and lung, 
LX-1) into their in vivo cancer drug screening program (Plowman et al 1997).  
L. R. Kelland has provided a standard operational procedure (SOP) for conducting a 
xenograft experiment (Kelland 2004). The SOP points out the importance of appreciating 
and understanding each of the many variables existing in the use of xenografts such as 
origin of the xenograft model, site of implantation, growth characteristics, treatment 
modality and experimental endpoint.  
Human tumor xenografts can be established by direct implantation of patient 
biopsies or via inoculation of human tumor cell lines. Xenografts derived directly from 
patient biopsies largely retain the morphological and molecular properties of the source 
tumors. In contrast, xenografts derived from cell lines show a more homogeneous, 
undifferentiated histology (and sometimes loss of the target receptors and proteins), 
probably due to the higher selection pressure in vitro during extensive culturing.  
While most xenograft experiments use s.c. implantation, there are many reports of 
differences in biological behavior when tumors are grown s.c. relative to orthotopically 
(Eccles 2002). It is recognized that not all xenograft models are usable for compound 
screening because of their growth properties. Sometimes growth is too slow, too 
inconsistent/erratic/non-linear with time, or they possess cystic or necrotic areas, even at 
relatively small tumor volumes. The occurrence of cystic or diffuse necrotic areas can 
often comprise 20-80% of the tumor mass, depending upon the model and number of 
passages in mice (Corbett et al 2002).  
2.3.2. Xenograft models for prostate cancer 
During the 1980s and 1990s, numerous chemotherapy trials in hormone refractory 
prostate cancer consistently showed poor response rates, without any trend towards 
improved survival (Yagoda and Petrylak, 1993). To increase the speed of selection 
between the large amounts of new chemotherapic drugs in prostate cancer treatment, 
the use of human prostate cancer xenograft models as a pre-screening system was 
proposed (Schröder et al, 2000). Such a xenograft-based pre-screening enabled a relatively 
fast selection of the best performing compound and new combinations. These preclinical 
studies allow validation of biomarkers, such as PSA, for their use in subsequent clinical 
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studies (van Weerden et al 2009). In xenograft models, circulating levels of PSA can be 
directly correlated to tumor burden, allowing validation of the relationship between PSA 
and tumor response during therapy (Limpens et al, 2006).  
Prostate cancer research has long been hampered by the limited availability of 
representative model systems. The classical models are the androgen-independent PC3 and 
DU145 cell lines and the androgen-responsive LNCaP cell line (Van Bokhoven et al, 2003). 
PC3 and DU145 lack expression of androgen receptor and PSA (Ruizeveld de Winter et al, 
1994). Although more clinically relevant, the androgen-responsive and PSA-secreting 
LNCaP cell line has its limitation in poor in vivo tumorigenicity and aberrant response to 
anti-androgens. This is due to a point mutation in the ligand-binding domain of the 
androgen receptor, rendering the cells sensitive not only to androgens, but also to other 
hormones such as progesterone and oestrogen, as well as to anti-androgens such as 
hydroxyflutamide (Veldscholte et al, 1992). 
The amount of human-derived xenografts was low, before a significant number of 
human prostate cancer xenografts were established in the 1990s (Van Weerden et al, 
1996). Thereafter, other groups, primarily in the United States, established several human-
derived xenografts, such as the CWR, MDA Pca, LuCaP and LAPC series of xenografts 
(Table 2.3). All these xenografts are available to other researchers (Bosland et al 1996, 
Navone et al 1999).The development of permanent cell lines from prostate cancer xenografts 
has been complicated, with the PC346 xenograft for a long time being the only xenograft 
resulting from a cell line (PC346C) (Marques et al, 2006). In recent years, a small number of 
xenograft-derived cell lines have been established. These include PC346C, 22Rv1, CWR-R1, 
DuCaP, LAPC-4, MDA Pca1, MDA Pca2a, MDA Pca2b and VCaP, all being karyotyped and 
compared in an extensive study by van Bokhoven et al (van Bokhoven et al 2003). The 
present set of xenograft models and cell lines represent the various disease stages of human 
prostate cancer, suitable for preclinical testing. 
Xenografts are well suited for molecular studies as they consist of pure human 
tumor tissue without contamination of human normal prostate tissue, which is always 
present in patient samples. Xenografts have been used in evaluation of abnormal genetic 
changes and gene profiles in human prostate cancer (van Weerden et al 2009). Genomic 
characterization shows that specific genomic abnormalities being detected in prostate 
cancer patients, such as mutations in the PTEN suppressor gene and genetic alterations in 
specific genes, also are prevalent in the xenografts (Vlietstra et al 1998, Maki et al 2007). 
Knowledge of the genomic profile of xenografts is crucial for selecting the most appropriate 
preclinical model, especially in the new era of targeted therapies requiring model systems 
with a specific molecular expression profile mimicking a specific disease stage or patient 
group (van Weerden et al 2009). 
 
 
 
31 
 
Table 2.3 Human prostate cancer xenografts (van Weerden et al 2009)  
Name Derived from Androgen responsive PSA AR Year 
PC-82 Prostate Yes Yes Yes 1977 
PC-133 Bone No No No 1981 
PC-135 Prostate No No No 1982 
PC-EW Prostate Yes Yes Yes 1981 
PC-295 LN Yes Yes Yes 1991 
PC-310 Prostate Yes Yes Yes 1991 
PC-324 TURP No No No 1991 
PC-329 Prostate Yes Yes Yes 1991 
PC-339 TURP No No No 1991 
PC-346 TURP Yes Yes Yes 1991 
PC-346I PC-346 No Yes Mutant 1992 
PC-346B TURP Yes Yes Yes 1991 
PC-346BI PC-346B No Yes Yes 1992 
PC-374 Skin Yes Yes Yes 1992 
TEN/12 Prostate Yes Yes Yes 1985 
LuCaP 23.1 Lymph node Yes Yes  1996 
LuCaP 23.8 Lymph node Yes Yes  1996 
LuCaP 23.12 Liver Yes Yes  1996 
LuCaP 35 Lymph node Yes Yes Yes 2003 
LuCaP 35V LuCaP 35 No   2003 
LuCaP 49 Metastasis? No No No 2002 
LAPC-3 AI TURP No Yes/no Yes 1999 
LAPC-4 AI LN Yes Yes Yes 1997 
LAPC-9 AI Bone Met Yes Yes Yes 2001 
CWR22 AD Met Yes Yes Mutant 1993 
CWR21 AD Met Yes Yes Yes 1993 
CWR31 AD Met Yes Yes Yes 1993 
CWR91 AD Met Yes Yes Yes 1993 
MDA Pca-31 Liver NA   1998 
MDA Pca-40 Liver NA   1998 
MDA Pca-43 Adrenal NA   1998 
MDA Pca-44 Skin NA   1998 
AR = androgen receptor; LN = lymph node metastasis; MET = metastasis; NA = not applicable; PC 
= prostate cancer; PSA = prostate-specific antigen; TURP = transurethral resection of the prostate. 
 
2.3.3. The orthotopic PC xenograft model 
The majority of preclinical studies are performed using subcutaneously (s.c.) 
implanted tumor cells or xenografts. With the establishment of new human prostate cancer 
cell lines from xenografts, orthotopic injections of PC346C, LAPC4 and LuCaP cell lines into 
the mouse prostate have become an alternative to the traditional s.c. xenograft model. 
The orthotopic model is especially important in evaluation of targeted therapies where 
expression of the tissue-specific target is essential and influenced by the implantation 
environment (van Weerden et al 2009). 
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A drawback of orthotopic transplantation in the mouse prostate is the difficulty of 
monitoring tumor growth with time. In the case of PSA-producing cells, plasma PSA may be 
used as an indicator of tumor burden, although this approach would lack validation of 
circulating PSA levels to actual tumor load (Thalmann et al 1996). To allow longitudinal 
studies of treatment efficacy in individual mice, a three-dimensional ultrasound micro-
imaging technique has been developed, allowing monitoring of prostate tumor growth (Kraaij 
et al 2002).  
2.3.4. Tumor characteristics of PC xenografts 
Initially, xenograft data was thought to have a poor prediction of human responses 
in clinical trials. As the three classical cell line models, PC3, DU145 and LNCaP, were 
strongly overrepresented, this may relate to the inappropriate choice of the model system 
(van Weerden et al 2009). With the present generation of xenograft models and the detailed 
knowledge of their genomic profiling, human xenografts are thought to be powerful tools in 
investigation of compound efficacy, specificity or identification of the mechanisms of action 
(van Weerden et al 2009). To perform relevant preclinical studies, the choice of the most 
appropriate model is essential and largely depends on the patient group the model is 
representing, and the expression of the target of interest. 
2.3.5 Androgen responsiveness in prostate cancer xenografts 
Hormonal treatment has been the main treatment in advanced prostate cancer since 
the first studies of Huggins and Hodges in the early 1940s. Since then, androgen 
responsiveness and androgen receptor (AR) characteristics, as well as PSA expression, 
have been the most important determinants for prostate cancer models (see Table 1.4, van 
Weerden et al 2009). Most tumors from prostate cancer patients that no longer respond to 
endocrine therapy have retained a functional AR, often with higher levels than in primary 
tumors (Ruizeveld de Winter et al 1994). It is suggested that the AR still is involved in 
growth regulation at this stage and that presently available anti-androgens not are capable 
of blocking this activity. The PC346 xenograft system and some of the CWR22, LuCAP 
and LAPC xenografts, show progressive, androgen-independent growth after androgen 
deprivation of tumor-bearing mice (Marques et al 2006). These resistant, androgen-
independent sublines are valuable assets in the study of androgen-resistant molecular 
pathways (Hendriksen et al 2006). Marques and colleagues established a set of anti-androgen 
(flutamide) resistant PC346C cell lines that mimic the clinical situation of androgen-
indipendent prostate cancer. This unique cell line can also be grown as xenografts, 
reflecting the various mechanisms of androgen-resistance also being observed in patients, 
including mutation, overexpression and downregulation of the AR (Marques et al, 2005).  
2.3.6. CWR22 xenograft model 
CWR22 is an androgen-dependent, human prostatic carcinoma xenograft established 
from a transurethral resection and grown subcutaneously in male athymic nude mice, each 
containing a s.c. implanted 12.5 mg testosterone pellet (Innovative research, Sarasota, FL) 
(Pretlow et al 1993). The CWR22 xenograft was taken from a stage D, Gleason score 9, 
prostatic carcinoma with osseous metastases and was the first serially growing primary 
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prostatic carcinoma (Pretlow et al 1993). Among the standard prostate tumor lines, CWR22 
has the least deviated sets of chromosomal aberrations from human prostatic carcinomas 
(Wainstein et al 1994).  
Upon androgen withdrawal, CWR22 PSA messenger ribonucleic acid (mRNA) and 
protein decrease rapidly, cells undergo apoptosis and tumors regress in size (Wainstein et al 
1994, Gregory et al 1995). After several months they recur in the absence of testicular 
androgens in a manner characteristic of human androgen-independent prostate cancers 
(Wainstein et al 1994, Gregory et al 1995). Thus, the CWR22 model allows the study of 
tumor behavior in both androgen-dependent and -independent states.  
In mice bearing CWR22 xenografts, Wainstein et al (Wainstein et al 1994) observed 
that serum PSA concentrations correlated with tumor size (Figure 2.7), and that blood levels of 
PSA decreased after androgen withdrawal. Gregory et al (Gregory et al 1995) demonstrated a 
decrease in CWR22 PSA mRNA levels within 48 h after androgen withdrawal.  
The slope of the graph in Figure 1.7 suggests that one can detect 1-2 mg of tumor 
with 50 μl of serum from the tail vein (Wainstein et al 1994). There was observed a 
significant metabolic decrease after irradiation in contrast to a lack of change in tumor 
volume and PSA for the same time frame in control mice (Dyke et al 2003). 
 
Figure 2.7. Correlation of PSA plasma concentration versus tumor volume. PSA plasma 
concentration was linearly related to tumor size up to 0,8 g, and continued to increase in 
larger tumors (Figure from Wainstein et al 1994) 
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2.4 Magnetic resonance imaging 
2.4.1. Physics of magnetic resonance imaging 
The phenomenon of Nuclear Magnetic Resonance (NMR) was independently 
discovered by two groups of physicists headed by F. Bloch and E. M. Parcell (Bloch et al 
1946/69, Bloch et al 1946/70, Bloch 1946, Purcell et al 1946). The basic physical effect in 
NMR is the interaction between nuclei with a nonzero magnetic moment (
1
H, 
13
C, 
17
O, 
31
P) 
and an external magnetic field. Due to abundance of hydrogen in human body, proton 
resonance is used in clinical imaging, thus, the equations in this chapter is written for the case 
of the proton.  
Under the influence of B0 the sample becomes magnetized. In thermal equilibrium the 
nuclear magnetization in the sample can be expressed as 
0BM            (2.2) 
where χ is the nuclear susceptibility, the degree of magnetization of a material in response to 
an applied magnetic field. 
Interaction between proton and external field can be described by the Hamiltonian 
0BH            
(2.3) 
where µ is the magnetic moment of a nucleus. The moment µ can be expressed as 
I
h


2

          
(2.4) 
where I
h
2
 is the angular moment of the nucleus and γ is a constant called the gyromagnetic 
ratio, γH = 42.6 MHz/T. 
The magnetic moment µ will precess around the axis of B0 at a frequency given by the 
Larmor equation 
0B            (2.5) 
where ω is the angular precessional frequency.  
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Excitation 
The NMR signal from a macroscopic sample is proportional to the equilibrium 
magnetization in the sample 
nM             (2.6) 
where n is the number of nuclei and <µ> is the average magnetic moment of nuclei. Because 
the energy of magnetic interaction is minimum when µ is parallel to B0, the probability that a 
nuclear magnetic moment is parallel to B0 is greater than being antiparallel to B0. In thermal 
equilibrium more magnetic moments in a sample are aligned with the external field. Because 
the energy of interaction does not depend on the component of µ in the plane perpendicular to 
B0 (transverse plane), the average transverse component of µ is zero. The equilibrium 
magnetization satisfies the following conditions: MZ = M0 > 0, MX = 0, MY = 0 where the z-axis 
is in the direction of B0. The signal which is detected in MR imaging is the varying magnetic 
flux in the xy-plane. The net magnetic moment in the z-direction has to be rotated or ‟flipped‟ 
into the xy-plane to achieve a detectable signal. This flipping is called excitation. 
The excitation of the protons is achieved by applying another magnetic field, B1, in 
the xy-plane. B1 is a linear polarized oscillating magnetic field with an oscillation frequency 
equal to the Larmor frequency ω and can be described as 
0,0,cos ,1,11,1  zyx BBtBB         
(2.7) 
The B1 field is applied a time τ and is called the radiofrequency (RF) pulse or the 
excitation pulse. During the time τ the magnetic field is flipped an angle 1B . 
If the RF pulse flips magnetization MZ into xy-plane it is called a 90˚-pulse, and if 
magnetization MZ rotates 180˚ then the RF pulse is called a 180˚-pulse. In practice flip angles 
can have all values from 0 to 180˚. 
Rotating Frame of Reference 
The stationary frame of reference, x, y, z, is called the laboratory system. A new frame 
x‟, y‟, z‟ is defined, which rotates around the z-axis with the Larmor frequency and is called 
the rotating frame of reference. In the rotating laboratory system, the magnetization vector 
will be static, provided the RF pulse is applied along the x axis. 
Relaxation 
After excitation, the magnetic dipole moment will try to re-establish equilibrium. This 
is called relaxation. In the Bloch model it is the thermal perturbations which cause relaxation 
of the longitudinal magnetization MZ back to its equilibrium state, while interactions between 
nuclei in the sample cause decay of the transverse magnetization Mxy (Bloch 1946). This 
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relaxation can be detected with external coils. The phenomenon is called free induction decay, 
FID. 
T1 relaxation 
The relaxation of MZ is described by 
1
0 )(
T
MM
dt
dM ZZ           (2.8) 
where T1 is a constant known as the spin-lattice relaxation time (Bloch 1946). A solution of 
this equation can be written as 
  )/exp()0( 100 TtMMMM zz  ,       (2.9) 
where Mz(0) is the initial value of Mz. 
 
Figure 2.8 Relaxation of longitudinal magnetization MZ to its equilibrium state and  T1 
constant.  
T1 relaxation occurs when protons excited to a higher state of energy, spin-up, returns 
to the lower state, spin-down. The transition between the energy states is stimulated by 
fluctuating magnetic field in the medium. They originate from molecular movements and can 
stimulate transitions between the energy states if the fluctuation has frequency components 
equal to the Larmor frequency. 
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The T1 constant is tissue-specific. A short T1 indicates that the tissue containing the 
protons suitable for the energy exchange. Fat has short T1, water has long T1, and solid tissue 
has intermediate T1 relaxation times. 
T2 relaxation 
Different nuclear moments precess at slightly different Larmor frequencies as a result 
of magnetic interactions between neighbouring nuclei. The presence of microscopic magnetic 
fields created by the nuclei themselves or by electrons causes dephasing of nuclear spins in a 
sample. This results in an exponential decay of Mxy that occurs with a characteristic time 
constant 2T  known as the spin-spin relaxation time. The dynamics of Mxy in the laboratory 
coordinate system is described by: 
0
2
0
2
, BM
T
M
dt
dM
BM
T
M
dt
dM
X
YY
Y
XX       (2.10) 
A solution of this equation can be written as 
)/exp()0()( 2TtMtM xyxy         (2.11) 
 
Figure 2.9 Relaxation of transverse magnetization and T2 constant 
In practice a more rapid decay of transverse magnetisation, known as the T2*-decay, is 
observed. It happens due to local magnetic field heterogeneity because of the nonuniformity 
of the applied field, spatially varying magnetic susceptibility in the media and destructive 
interference of the signal produced by different nuclei in the volume. The T2*-decay can be 
determined by: 
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
          (2.12) 
where ΔB0 is the inhomogeneities in the magnetic field. 
Water has long T2 relaxation time and is bright at T2-weighted images, while fat has 
short T2 relaxation time and appears dark on T2-weighted images.  
Spin echo 
Fast dephasing of nuclear spins due to magnetic field heterogeneity causes a 
significant loss of signal. The phenomenon of magnetic dipole moments refocusing in x‟y‟ 
plane by a 180°pulse after a 90°excitation RF pulse was discovered by E. Hahn (Hahn 1950) 
and is known as spin echo. 
The series of RF pulses shown on Figure 2.10 is called spin echo sequence.  
 
Figure 2.10 FID and spin echo signal produced by a spin echo sequence.  
The sequence starts with an excitation 90° pulse that flips a net magnetic dipole 
moment into x‟y‟ plane (Figure 2.11a). Due to different Larmor frequencies of dipole 
moments after a period of time they will be out of phase (Figure 2.11b). After time τ a 
180°pulse is applied. This causes refocusing of dipole moments (Figure 2.11c). At the time 
2τ, the echo time (TE), the dipole moments will be in phase again and a new signal can be 
registrated (Figure 2.11d).  
If the 180°pulses are repeated a series of echoes can be detected. The amplitude of the 
signal is declining with the T2 relaxation constant.  
39 
 
 
Figure 2.11. Refocusing of dipole moments in the rotating coordinate system. 
Image reconstruction. 
The detected signal is a sum of contributions from all the excited magnetic dipole 
moments in the sample volume. To achieve an image with spatial resolution, signals from 
smaller volumes need to be separated. It can be achieved by introducing magnetic field 
gradients which causes the Larmor frequency to be a function of position. Gradients in the x, 
y and z directions are required to obtain spatial information: 
• The slice select gradient, Gz 
• The frequency-encoding gradient, Gx 
• The phase-encoding gradient, Gy 
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The Slice Select Gradient 
In addition to the external magnetic field, B0, a linear magnetic gradient in the z-
direction,Gz, is applied  


 zGBB Z0         (2.13) 
Since the Larmor frequency is proportional to the strength of the magnetic field, the 
Larmor frequency will have a z-dependence given by 
)( 0 ZzGB           (2.14) 
The magnetic dipole moments outside the slice will not be excited as their Larmor 
frequencies differs from the frequency of the B1. 
Frequency and Phase Encoding 
Phase and frequency distribution within the selected slice can be modified by applying 
gradients in the x- and y-directions. 
After applying the gradient in the y-direction, Gy the magnetic dipoles will rotate with 
a frequency determined by their y position. The phase angle α=ωt is defined by 
krrdttGtr y   )(),(
0

        (2.15) 
where r=ix+jy defines the position of the dipole, k represents coordinates in spatial frequency 
space (k-space) and has the unit radians per meter. The k-space is the Fourier transform of the 
MR image and represents the spatial frequency distribution. The central part of k-space 
contains low spatial frequency information (contrast), whereas the outer parts of k-space 
contain high spatial frequency information (detail, edges). 
After a time ty, Gy is turned off, resulting in the magnetic dipoles to precess with the 
same frequency. Due to varying precession speed while Gy is on, the magnetic dipole 
moments will have different phase dependent on the y position. This technique is called phase 
encoding, and the phase of the individual y positions is given by 
ykytGt yyyyyy          (2.16) 
The gradient Gx turns on while the Gy gradient is active and during detection of the 
signal. This is called the read-out gradient. The magnetic dipole moments will during 
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detection of the signal precess with a frequency dependent on the x position. To be able to 
image the entire slice, this sequence is repeated with a new Gy in every repetition, resulting in 
a set of FIDs with different Gy. To make an image with Nx×Ny points, Nx points are needed in 
every FID and the sequence must be repeated Ny times. In terms of k-space, a single line 
along kx is sampled following each RF pulse. In MRI the pulse sequence using this sampling 
principle is called gradient echo (GRE) sequence. This sequence is faster than spin echo 
sequence due to absence of refocusing pulse and therefore shorter repetition and echo times. 
The magnetization M(r,t) gives rise to the detected signal. The total transverse 
magnetization is given by 
))(exp(),())(exp(),(),(),(
0
ykxkjyxMrdttGjorMtrMyxM yx
t
  (2.17) 
The total signal is a sum of contributions from all sample volumes. By applying an 
inverse Fourier transformation, signal for a given slice signal can be defined as  
 
slice
yxyx dxdyykxkjyxMCkkS ))(exp(),(),(     (2.18) 
where C is a constant. 
Imaging Coils 
A coil is an electrical device composed of a single or multiple loops of wire. The coil 
can either generate a magnetic field, a gradient coil, or detect an oscillating magnetic field as 
an electrical current induced in the wire, a RF coil (Hashemi and Bradley 1997). 
Gradient coils include the imaging gradient coils and the shim coil. The imaging 
gradient coil causes a perturbation in the magnetic field homogeneity which results in spatial 
encoding. Shim coils are used to produce a magnetic field which cancels spatial variations in 
the external magnetic field, B0. Transmit and/or receive RF coils include the single phase or 
quadrature coils, the surface or volume coils, called solenoid, and the phased array coils. The 
quadrature coils have two receivers which are 90° to one another in order to distinguish 
between the real- and imaginary components of the received signal. The solenoid coils can be 
wrapped around the patient to increase the SNR. Phased array coils contain multiple small 
surface coils. These coils allow faster scanning with finer details and increased signal to noise 
ratio (SNR). 
Coil for Imaging of Small Animals 
For small animal imaging in clinical whole-body MRI scanners, high spatial 
resolution images of thin tissue sections, high SNR and high B1 field homogeneity are needed. 
While gradient strength in modern scanners is sufficient, the sensitivity of conventional coils 
42 
 
does not satisfy the demands. To be able to image small animals, an open gap transmit-receive 
MR coil for imaging small animals in a clinical whole-body 1.5 T MR scanner can be used 
(Seierstad e al 2007). The coil is shown in Figure 2.12. 
The coil is tuned to a frequency close to the expected Larmor frequency of the protons 
at 1.5 T (63.89 MHz). The tuning creates a higher output signal for a given input signal and 
minimizes losses due to external sources with other frequencies. The coil provides 
examinations with nearly homogeneous sensitivity in the entire body at a spatial resolution of 
1-2 mm. For all MR experiments with the coil, a 30 dB attenuator has to be connected to the 
transmit line of the MR scanner in order to reduce the excitation signal. There is no need for 
hardware modifications of the MR scanner. 
Contrast in MR Imaging 
MRI is an important diagnostic tool because it provides exquisite contrast between 
various soft tissues, enabling identification of pathologic processes. Variations in relaxation 
times, T1 and T2, and the amount of protons per unit volume (known as proton density, N(H)) 
are the predominant sources of contrast in 
1
H MRI. The use of T1 and T2 in identification of 
pathology is based on differences in relaxation times between malignant and benign tissues 
(Damadian 1971). 
T1 Contrast 
When tissues with different T1 relaxation times experience excitation pulses, tissues 
with short T1 will restore their longitudinal magnetization more rapidly and have a greater 
transversal magnetization than tissues with long T1. As a result, imaged tissues with short T1 
are brighter than tissues with long T1. These images are known as T1-weighted images. 
Improved T1 contrast is obtained by using short repetition times (TR) such that differences in 
T1 relaxation times between the tissues are large, while keeping the echo time (TE) short to 
avoid influence of differences in T2 relaxation among the tissues.  
 
Figure 2.12. The transmit-receive MR coil for imaging of small animals in a clinical 1.5 T 
MR scanner.  
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T2 Contrast 
In T2 weighted images tissues with long T2 appears bright, whereas tissues with short 
T2 appears dark. These images are obtained by using long TR to avoid the differences in T1 
relaxation times, and a long TE to maximize the differences in T2 relaxation times between 
the tissues.  
Proton Density Images 
Proton density is the number of protons per unit volume. Proton density-weighted 
images are produced using a long TR to avoid differences in T1 relaxation times and a short 
TE to avoid differences in T2 relaxation times.  
Contrast Agents 
Contrast agents can enhance MR image contrast by altering the T1, T2 and T2
*
 
relaxation times and are used in diagnostic MRI to achieve better assessment of physiological 
and anatomical conditions or to improve detection of malignancy. These substances are 
administered internally, and must therefore possess low toxicity and easily be excreted from 
the body. 
Paramagnetic ions with a number of unpaired electrons such as Gd
3+
 and Mn
2+ 
are 
used as contrast agents because of their high relaxivities. To reduce the toxicity of these ions 
for in vivo applications, they are chelated to special molecules. Gadolinium pentetate (Gd-
DTPA), the currently most used MRI contrast agent, is a chelate composed of gadolinium 
ions and diethylenetriaminepentaacetic acid (DTPA). Chelation of gadolinium ions decreases 
the effective amount of water molecules that interact with the paramagnetic ions, thus the 
relaxivities of Gd-DTPA are less than the corresponding relaxivities of the free gadolinium 
ion. Gd-DTPA is typically administered at a dose of 0.1 - 0.2 mmol/kg.  
Rapid MR Imaging 
Rapid MRI techniques were developed to reduce motion artifacts and scan times in 
diagnostic MRI. Reduction in scan time is achieved by using gradient-echo imaging with 
short TRs, echo-planar imaging (EPI) and fast spin-echo imaging (FSE). 
Rapid Gradient-Echo Imaging 
There are two different techniques for rapid gradient-echo imaging. The first one is 
Spoiled Gradient-Echo Imaging that employ RF and gradient spoiling to destroy the 
transverse magnetization after each signal acquisition while maintaining the steady-state 
longitudinal magnetization. The second approach is Refocused Gradient-Echo Imaging with 
gradient refocusing used to maintain both transverse and longitudinal components of the 
magnetization in equilibrium. This means that a single refocused magnetization vector is 
present in the transverse plane at each RF-excitation and no „splitting‟ of the transverse 
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magnetization occurs. The effects of field inhomogeneities are refocused (no T2* effect) and 
“true” T2 decay is observed.  
Accelerated k-space trajectories 
In spin echo and GRE sequences a single line in k-space is read out per one RF pulse 
(one TR interval). Scan time is therefore long, especially when strong T2 weighting required. 
The acquisition time can be reduced by acquiring multiple k-lines per TR-interval. Two main 
techniques that use this approach are EPI and FSE. 
FSE is a spin echo pulse sequence including a series of rapid 180° rephasing pulses 
and multiple echoes, changing the phase encoding gradient for each echo. Compared with 
conventional spin echo sequence where a single ky-line is read out per TR, multiple ky-lines 
are read in FSE. If all ky-lines are read out after a single 90° pulse followed by Ny 180° pulses 
then the sequence is called Single Shot FSE (SSFSE). The number of echoes acquired in each 
TR interval is called echo train length (ETL). For example, if an ETL=10 then this will result 
in 10 fold reduction of scan time relative to scan time used to cover the same volume with 
single spin echo.  
In the EPI sequence, multiple k-lines are acquired following a single excitation pulse 
and a complete EPI can be acquired in approximately 100 ms. But in addition to speed, EPI is 
very sensitive for field inhomogeneities which results in many artefacts. 
2.4.2. Dynamic contrast enhanced magnetic resonance imaging 
 
Figure 2.13 Two compartment pharmacokinetic model. After an intravenous bolus 
injection of low molecular weight contrast agent, it mixes with plasma and can 
penetrate through damaged capillary membrane (e.g. in tumors). The transfer is 
described by a constant of the transport of contrast agent from plasma into the EES,K
trans
, and 
a transport constant of backflux from EES to plasma,Kep. Ve is a fraction of EES in total 
tissue volume 
Dynamic contrast enhanced (DCE) MRI is a method of tracing dynamic effects in 
MR contrast after a bolus injection. When a paramagnetic, low-molecular weight contrast agent 
is injected intravenously, it enters the blood vessels and subsequently passes into the extravascular 
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extracellular space (EES) (Figure 2.13). A high first pass extraction occurs in most normal 
tissues, while in tumors, typically 12-45% of the contrast media leaks into the EES during the 
first pass (Daldrup et al 1998). Then the contrast agent freely diffuses within the interstitial 
space until whole body distribution and renal excretion lowers the vascular concentration below 
that in the interstitial space and the contrast medium passes back into the vascular space. Three 
major factors determine the behavior of low molecular weight contrast agents during the first 
few minutes after injection: 1) blood perfusion (contrast agent delivery), 2) transport of 
contrast agent across vessel walls and 3) diffusion of contrast medium in the interstitial space. 
If the delivery of the contrast medium to a tissue is insufficient to maintain a high vascular 
concentration compared to that in the EES (flow-limited situations or the vascular permeability is 
greater than inflow), then blood perfusion will be the dominant factor determining contrast agent 
kinetics, which is the situation in tumors. As low molecular weight contrast agents do not cross 
cell membranes, its volume of distribution is the volume of the EES, Ve.  
The most commonly used mathematical model for describing contrast agent distribution 
is the two-compartment model, also called the Tofts model (Figure 2.13).  
The dynamics of contrast agent concentration in tissue can be described by the following 
equation: 
)()(
)(
tCktCK
dt
tdC
tpep
transt         (2.19) 
where K
trans
 is a constant describing the transport of contrast agent from plasma into the EES, kep is 
a transport constant describing backflux from EES to plasma, Cp and Ct are contrast agent 
concentration in plasma and EES, respectively. K
trans
 is a measure of the permeability surface area 
product of the capillary walls in tissue. The constant kep is related to K
trans
 and Ve as 
e
trans
ep
V
K
k            (2.20) 
The contrast agent concentration in plasma Cp(t) is determined by the arterial input 
function (AIF). For Gd-DTPA, the AIF can be approximated as: 
)exp()exp()( DtCBtAtC p         (2.21) 
where A [mM], B [s
-1
], C [mM] and D [s
-1
] are constants determined by experiments. The first 
term of the equation describes the fast diffusion from blood vessels into EES, the second one 
describes slow elimination of Gd-DTPA by kidneys (Tofts 1997).  
Using the equations for plasma concentration and the dynamics of contrast agent 
concentration, the equation of contrast agent concentration in tumor tissue will be as 
following: 
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where D is the dose of Gd-DTPA injected. 
The ability of the contrast agent to enhance the proton relaxation rate is defined in terms of 
relaxitivity: 
GdCrR
T
R 2,12,1
0
2,1
2,1
1
         (2.23) 
where R
0
1,2 are relaxation rates without presence of contrast agent, CGd is concentration of contrast 
agent, r1,2 are relaxivities of contrast agent and have units of mM
-1
s
-1
. (Bjørnerud 2006). 
The contrast agent concentration can be estimated using a method introduced by Hittmair 
et al. (Hittmair et al 1994). It is based on a T1-weighted RF-spoiled GRE sequence with TE less 
than T2*. Signal intensity in acquired images can be approximated as following 
))exp(1(
1
max
T
TR
KSS          (2.24) 
where K is a correction factor dependent on the flip angle. Smax is the maximum signal intensity 
and can be estimated from proton density images as following 

 
10sin
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sin)( 10max

 SHNS        (2.25) 
where N(H) is the proton density and Sα=10° is the signal intensity in proton density images with 
a flip angle of 10°, α is the flip angle used in T1 weighted images. 
Relaxivity changes can be calculated using images taken before (precontrast) and after 
(postcontrast) administration of contrast agent using the following equation 
Gd
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11      (2.26) 
where CGd is the measured concentration of Gd-DTPA in tissue, C is a constant, Spre and Spost are 
signal intensities for pre- and postcontrast images, respectively. 
C can be calculated if we introduce two phantoms, one (fant0) without contrast agent, 
another (fant1) with known Gd-DTPA concentration C1 in the same image. Constant C can be 
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determined as following 
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        (2.27) 
Measured concentration of contrast agent in tissue CGd can then be calculated using 
equation (2.26). The CGd(t) curve is approximated using the Tofts model curve Ct(t) (2.22). K
trans
, 
Ve and kep can then be found.  
2.4.3. Diffusion-weighted magnetic resonance imaging  
Biological diffusion  
(Based on Alexander et al 2007 if else is not stated) 
Diffusion is a random transport phenomenon, describing the transfer of material (e.g., 
water molecules) from one spatial location to other locations over time. The Einstein diffusion 
equation (Einstein 1956) states that the diffusion coefficient, D (in mm
2
/s), is proportional to 
the mean squared-displacement, Δr2 , divided by the number of dimensions, n, and the 
diffusion time, ∆t: 
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The diffusion coefficient of pure water at 20°C is roughly 2.0 × 10
−3 
mm
2
/s and 
increases at higher temperatures. In the absence of boundaries, the molecular water 
displacement is described by a Gaussian probability density 
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The diffusion of water in biological tissues occurs inside, outside, around, and through 
cellular structures. Water diffusion is primarily caused by random thermal fluctuations, and is 
modulated by the interactions with cellular membranes and organelles. Cellular membranes 
hinder the diffusion of water, causing water to take more tortuous paths, thereby decreasing 
the mean squared displacement. The diffusion tortuosity and corresponding apparent 
diffusivity may be increased by either cellular swelling or increased cellular density. Thus, 
necrosis, which results in a breakdown of cellular membranes, decreases tortuosity and 
increases the apparent diffusivity. In fibrous tissues like white matter in brain, water diffusion 
is unimpeded in the direction parallel to the fiber orientation. This makes the diffusion in 
fibrous tissues anisotropic. 
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The diffusion tensor describes anisotropic diffusion behavior (Basser et al 1994, 
Basser et al 1994/2.) The model of Basser describes anisotropic diffusion by a multivariate 
normal distribution 
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where the diffusion tensor is a 3×3 covariance matrix: 
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describing the covariance of diffusion displacements in three dimensions normalized by the 
diffusion time.  
The diagonal elements, Dii > 0, are the diffusion variances along the x, y and z axes, 
and the off-diagonal elements are the covariance terms being symmetric about the diagonal, 
Dij = Dji. Diagonalization of the diffusion tensor yields the eigenvalues l1, l2 and l3 and 
corresponding eigenvectors ê1, ê2 and ê3, describing the directions and apparent diffusivities 
along the axes of principle diffusion. Diffusion is considered isotropic when the eigenvalues 
are nearly equal (e.g., l1 ~ l2 ~ l3) and anisotropic when the eigenvalues are significantly 
different in magnitude (e.g., l1 > l2 > l3). The eigenvalue magnitudes are affected by changes 
in local tissue microstructure, both diseased and normal physiological changes. Diffusion 
coefficient in case of isotropic diffusion is determined as D = (l1+l2+l3)/3. 
MRI and diffusion 
Changes in T1 and T2 relaxation are often insufficient to detect or characterize lesions 
(Charles-Edwards and deSouza 2006), thus MR sequences have been sensitized to measure 
the “apparent diffusivity”. The diffusional motion measured by MRI relates to the mean path 
length, L, travelled by protons within a specific observation time period, the diffusion time, as 
a result of the thermally driven, random motion (Fig. 2.14 Charles-Edwards and deSouza 
2006). 
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Figure (2.14). The mean path length L for regions with different cell density. Due to high 
density of the cells the mean path length is L is shorter than in low cell density areas (e.g. 
necrosis cores) (Charles-Edwards and deSouza 2006) 
Diffusion-Weighted Image Acquisition 
Diffusion sensitivity of MR sequences is achieved using a bipolar gradient pair. This 
sequence was originally called the Stejskal-Tanner sequence. 
 
Figure (2.15) The Stejskal-Tanner diffusion weighted sequence (Bjørnerud 2006). 
The gradient pulses attenuate the signal coming from spins that are diffusing in the 
presence of the gradient pulses. The first gradient pulse dephases the magnetization and the 
second rephases the magnetization. For stationary, non-diffusing, protons, the phases induced 
by both gradient pulses will cancel producing no signal attenuation from diffusion. The net 
phase effect for moving protons due to gradient pair is described as following 
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GRrrG   )'(        (2.32) 
where γ is the gyromagnetic ratio, G is the magnitude of the diffusion-encoding gradients, δ is 
the duration of each diffusion encoding gradient, and Δ is the time interval between the 
leading edges of the diffusion-encoding gradients 
The signal intensity for the resulting image can be written as following 
)exp()0())
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    (2.33) 
where b is a parameter determining the amount of diffusion weighting in the sequence and has 
the units of s/m
2
: 
)
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  Gb         (2.34) 
In our experiment, diffusion tensor imaging was achieved using a SSFSE-based 
diffusion MR acquisition. It provides images without the significant degree of spatial 
distortions that single shot EPI sequences suffers from. For diffusion tensor imaging, 
encoding a minimum of six non-collinear diffusion encoding directions are required to 
measure the full diffusion tensor. A wide variety of diffusion tensor encoding strategies with 
six or more encoding directions has been proposed (Charles Edwards and de Souza 2006).  
Image analysis 
A DW-MRI sequences‟ sensitivity to diffusion can be adjusted by altering the 
combination of gradient pulse amplitude, the time for which the gradients are applied and the 
time that elapses between their application. The higher the b-value, the more sensitive an 
image is to the effects of diffusion. In biological objects diffusion is usually anisotropic or a 
mixture of diffusion in different compartments each having different diffusion coefficients, D. 
Therefore, the “apparent diffusion coefficient” (ADC) was introduced to measure a diffusion 
coefficient obtained in in vivo studies. ADC describes the displacement of protons during the 
application of the diffusion gradients (Mori and Barker 1999): 
)ln(
1 0
bS
S
b
ADC          (2.35) 
where S0 is the signal intensity without diffusion weighting, and Sb is the signal intensity with 
diffusion gradient. An ADC map created by combining two images with different b-values, 
the lower which is not large enough to remove the effects of perfusion (b values less than 300 
s/m
2
), contains information about perfusion as well as diffusion components. To differentiate 
between perfusion and diffusion multiple b-values are needed. 
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Most clinical machines create ADC maps by averaging three diffusion-weighted 
images which have encoded diffusion in the slice, frequency (read) and phase-encode 
directions, respectively. Such techniques are termed „isotropic‟ and the associated averaged 
ADC maps sometimes termed „trace‟ or „isotropic‟.  
Pathological correlates  
The majority of diffusion MRI performed clinically to date has focused on the 
extracellular water diffusion. In highly cellular tissues, such as tumors, extracellular water 
diffusion is restricted, leading to a short diffusional path and a reduced ADC. Cystic or 
necrotic portions of tumors have few structural barriers present and have a high ADC. ADC 
maps, derived from diffusion-weighted imaging, can therefore provide a non-invasive 
measure of cellularity (Herneth et al 2003), being a promising tool in diagnosis, treatment 
planning and monitoring. 
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Chapter 3 
Materials and Methods 
3.1. Description of the experiment 
The experiment consisted of 32 male mice with subcutaneously implanted CWR22 
xenografts randomized into 4 groups of 8 mice:  
1. CWR22 control 
2. CWR22 irradiated 
3. CWR22CA control 
4. CWR22CA irradiated 
Mice in group 1 and 2 were included in the experiment when the tumors‟ shortest 
diameter reached 8 mm. Mice in group 3 and 4 were castrated when the shortest tumor 
diameter was 13 mm. Due to castration the tumors regressed and at a shortest tumor diameter 
of 8 mm these animals were included in the experiment. The day of inclusion is called day 0.  
MRI was performed at day 0, day 1 (24 h) and day 9. The tumors in the irradiation 
groups were irradiated with a single fraction of 15 Gy after the baseline MRI at day 0. When 
the tumors‟ longest diameter reached 16mm in two of the mice in one group or 30 days after 
inclusion into experiment (depending of what condition was satisfied first), the mice were 
sacrificed, and blood and tumor tissue were collected. An additional 8 mice with identical 
weight as the other mice were used to obtain vascular input functions (VIFs) by imaging the 
left ventricle. A schematic illustration of the experiment is shown in Figure 3.1. The 
individual parts of the diagram will be explained in detail in this chapter.  
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Figure 3.1. Schematic view of the experiments. The bottom row (B) shows the experimental 
procedure in group 1 and group 2 (CWR22), and the upper row (A) shows the experimental 
procedure in group 3 and group 4 (CWR22CA). Tumor sizes were measured two times a 
week from implantation until the mice were sacrificed. 
3.2. Substances used in experiment 
3.2.1. Anesthesia 
An ampoule containing powder of 125 mg tiletamine and 125 mg zolazepam (Zoletil 
vet., Virbac, Carros, France) was mixed with 10 ml of 20 mg/kg xylazine solution (Narcoxyl 
vet, Roche, Basel, Switzerland) and 0.5 ml 10 mg/ml butorphanol solution (Torbugesic, Fort 
Dodge Laboratories, Fort Dodge, IA). The resulting stock solution was further diluted 1:5 
with sterile water to prepare a mice Zoletil solution. Both stock and mice Zoletil solutions 
were stored at 4 °C, with new stock solution prepared every month. To obtain a full 
anesthesia, mice were s.c. injected with 75 μl per 10 g of weight, giving a total dose of 18 
mg/kg zolazepam, 18 mg/kg tiletamin, 0.7 mg/kg butorphanol and 29 mg/kg xylazin. Full 
anesthesia lasted for approximately 2 hours.  
Eye ointment containing 20% liquid paraffin and 80% vaseline (Simplex, Ophtha, 
Gentofte, Denmark) was used during every anesthesia to prevent the eyes from dryness. 
3.2.2. Analgesia 
An ampoule containing 0.3 mg buprenorphinum (Temgesic, Schering-Plough, 
Brussels, Belgium) was diluted in sterile water to a total concentration of 0.03 mg/ml. The 
solution was administrated subcutaneously at a dose of 0.1 ml per 20 g mouse, resulting in a 
total dose of 0.15 mg/kg. The effect lasted for approximately 6 hours.  
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3.2.3. Contrast agent 
Gadopentetate dimeglutamine (Gd-DTPA) (Magnevist, Schering, Berlin, Germany) 
diluted in heparinized saline (produktnavn, sted, land) to 0.06 M was used as the contrast 
agent. Heparinized saline contained 500 IE of heparin per 100ml. 
3.3. Animal model 
3.3.1. Mice 
Locally bred sexually mature male NCR nude mice (similar to commercially available 
BALB/c nude mice) weighing 25 – 35 g and aged 6 to 8 weeks old were used in this study. 
The National Committee on Research on Animal Care approved the animal protocol, and the 
experiment was performed according to Interdisciplinary Principles and Guidelines for the 
Use of Animals in Research, Marketing and Education (New York Academy of Science, New 
York, NY). The mice were kept under specific pathogen-free conditions at constant 
temperature (21.5 – 22.5 °C) and humidity (50 – 60 %). The mice were given sterilized food 
and water ad libitum. Mice were sacrificed by neck dislocation at the end of experiment. 
3.3.2. Xenografts 
The human androgen-dependent xenograft CWR22 was used. Tumor tissue measuring 
approximately 2 × 2 × 2 (mm)
3
 was subcutaneously implanted into the left flanks of the mice 
to generate CWR22 xenografts. Mice were anesthetized with zoletil solution before 
implantation. 
The CWR22CA xenografts were achieved by androgen deprivation therapy using 
surgical castration of animals with CWR22 xenografts. At a shortest tumor diameter of 13 
mm the animals were surgically castrated and allowed to partially regress until the shortest 
tumor diameter was 8 mm, before they were included into the experiment. Mice were 
anaesthetized with Zoletil solution and analgesized with Temgesic solution during the 
castration procedure.  
Tumor volumes were estimated from caliper measurements two times a week from 
implantation until the end of the experiment using the formula V = (length × length × 
width)/2, with length being the longest diameter across the tumor and width the corresponding 
perpendicular.  
3.4. PSA analysis 
Blood to PSA analysis were collected from each mouse at day 0, day 1, day 9 and 
when the mice were sacrificed. A blood volume of 50 to 150 µl was collected from the tail 
vein using a non-heparinized capillary tube, before it was allowed to clot and centrifuged to 
collect serum. The serum was frozen at -80°C until PSA measurements were conducted. The 
ProStatus(tm) PSA Free/Total assay was used. It is a solid phase fluoroimmunometric assay 
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based on the direct sandwich technique containing three monoclonal antibodies derived from 
mice. The principal scheme of the assay is showed in Figure 3.2. Europium-labeled antibodies 
directed against an antigenic site which is accessible only in free PSA are reacted with solid 
phase bound free PSA. Simultaneously, samarium-labeled antibodies directed against 
antigenic site common to both free and complexed PSA are reacted equimolarily with bound 
free and complexed PSA. Enhancement solution dissociates europium and samarium ions 
from the labeled antibody into solution where they form highly fluorescent chelates with 
components of the enhancement solution. The fluorescences in each well are then measured. 
The europium fluorescence of each sample is proportional to concentration of free PSA in the 
sample and the samarium fluorescence is proportional to the concentration of free and 
complexed PSA (total PSA) (Soini and Kojola 1983, Hemmila et al 1984, Lovgren et al 
1985). Reference standards were used to calibrate the results. 
 
Figure 3.2.A scheme of The ProStatus (tm) PSA Free/Total assay used to measure PSA 
concentration in plasma.  
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3.5. Radiation therapy 
The tumors in the two irradiation groups (groups 2 and 4) received a single fraction of 
15 Gy on day 0 (after the MRI) using a 
60
Co source (Mobaltron 80, TEM Instruments, 
Crawley, UK) having a dose rate of 0.6 Gy/min. The 
60
Co source is contained inside a 
stainless-steel capsule sealed by a welding, which is placed in another steel capsule to prevent 
any leakage of the radioactive material, see Figure 3.3. The 
60
Co source emits radiation when 
the 
60
Co nucleus decays to 
60
Ni by emission of β-particles and two photons per disintegration 
with energies of 1.173 MeV and 1.332 MeV. These γ-rays constitute the useful treatment 
beam. The β-particles are absorbed in the cobalt metal (Khan 1994)  
 
Figure 3.3. The 
60
Co-unit used in irradiation of the CWR22 and CWR22CA xenografts. 
The megavolt beam produced by this cobalt source gives an initial dose buildup with 
depth, resulting in maximum dose at a depth of 4 mm. To achieve a homogeneous dose 
deposition within the tumor volume, a 5 mm thick polystyrene bolus was placed on top of the 
tumor. A bolus is a tissue-like material that compensates irregular contours and surface and 
creates a build-up region for reaching a maximum even dose in whole tumor. For the 
60
Co 
unit at 80cm distance, the buildup dose distribution in polystyrene for a 10 x 10 cm field is 
givenin Table 3.1. 
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Depth, mm Dose, % of max 
0 18.0 
1 70.5 
2 90.0 
3 98.0 
4 100.0 
5 100.0 
Table 3.1: Buildup dose distribution in polystyrene for a 10 × 10 cm field by use of a 
60
Co 
Unit (Khan 1994)  
The 
60
Co unit was initially measured the 15.09.1996, with the dose rate of A
-
1
(0)=31.35 s/Gy. Since 
60
Co sorce is decaying, the dose rate is adjusted monthly according to 
the decay constant of the 
60
Co source. Correct dose rate at the date of radiation, A
-1
(t), is 
calculated by the following formula (3.1) 
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2ln
)()( 15
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15
11 tAn
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tAtA
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  (3.1) 
where A
-1
(t15) is the dose rate at the 15
th
 days of the last month, Th is the half-life time of 
60
Co 
(1925.1 days), and n the number of days since the 15
th
. The unit of dose rate is s/Gy. The 
radiation time in seconds was found by multiplying the dose rate A
-1
(t) with the dose in Gy. 
During radiotherapy, only the tumor area of anesthetized mice was irradiated, whereas 
the rest of the body was kept outside the radiation field. Figure 3.4 shows mouse position in a 
radiation field represented on the picture by a square of white paper. In previous experiments 
(Røe 2006) measurement of dose in the center and the corner of the 10x10 square was made. 
The correct dose was found using a phantom, a plastic glove filled with water. The radiation 
field was adjusted to 10x10cm and the distance between source and phantom was 80 cm. In 
the center and in the phantom in the corner several TLD chips were placed. Measuremet 
showed that a central dose of 18.45Gy corresponded to 15Gy dose 1.5 cm into radiation field 
from the outer corner. When calculating radiation time a central dose was used. It was also 
showed that dose that dose outside the radiation field was 50 times lower than in the center. 
According to this, a mouse was placed in a radiation field as shown in figure 3.4. A tumor is 
positioned 1,5cm from outer corner, while the rest of the body placed outside the field. 
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Figure 3.4. An illustration of a mouse in the radiation field (a), and a mouse with bolus (b).  
The white paper square was a guide for positioning of radiation field. Center of the field is 
marked with a cross. A tumor was positioned 1.5 cm from the outer corner, while the rest of 
the body was positioned outside the radiation field.  
3.6. Magnetic resonance 
3.6.1. Preparation for MR acquisition. 
First, the mice were weighed to calculate the amount of contrast agent (0.1 ml/10 g of 
body weight).Then, the mice were anesthetized and eye ointment was applied. A heparinized 
24-gauge catheter was inserted into the tail vein and attached to a cannula containing the 
saline-diluted Gd-DTPA. The mouse was placed in a stretcher made of extruded polystyrene 
thermal insulation material (Styrofoam) as shown in Figure 3.5. The loaded mouse coil was 
tuned with a vector impedance meter (Hewlett Packard 4193A) to 63.89 MHz. This frequency 
is the Larmor frequency of the protons at 1.5 T, whose resonance signal is being detected. The 
tuning matches the MR system before acquisition of data and results in a higher output signal 
and minimizes losses due to external sources with other frequencies.  
 
Figure 3.5. (a) An illustration of a mouse in the stretcher before placement in the MR coil, 
and (b) the mouse coil used in the MR experiments.  
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3.6.2. MRI acquisition 
MR imaging was performed using a 1.5 T whole-body clinical MR system (Signa, 
General Electrics, Milwaukee, USA) at the MR facility at Rikshospitalet-Radiumhospital HF 
(Oslo university hospital at the present moment) (Figure 3.6). The volume to be excited in 
imaging of mice is substantially less than the volume to be excited in clinical imaging of 
patients. Thus, the transmitted signal was attenuated with 30 dB during all experiments. The 
mouse coil was attached to the clinical MR scanner in the connector for standard 
transmit/receive extremity coils used for MR. The coil was placed in the iso-center of the MR 
scanner. The temperature of the mouse was maintained at 38°C during acquisition using a 
water-heating pump with warming pad around the coil. 
 
Figure 3.6. The 1.5 T clinical MR scanner used in the experiments. A mouse coil from figure 
3.5(b) is placed outside the magnet. 
The excitation field B1 must be perpendicular to the main magnetic field B0, hence 
themouse coil was placed as illustrated in Figure 3.7. 
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Figure 3.7. Placement of the mouse and mouse coil in the MR scanner. The excitation field 
of the coil, B1, is perpendicular to the main magnetic field, B0. A = anterior, P = posterior, R 
= right, L = left, S = supine, and I = inferior. 
The MR-protocol given in Table 3.2 was used for all investigations. All imaging 
parameters were kept the same throughout the experiment. 
Table 3.2 The MR-protocol 
Sequence No Type of sequence Scan time 
1 Localization 0:41 
2 T2-weighted image 2:40 
3 Tensor diffusion images with b = 0 and 50 s/mm
2
 1:05 
4 Tensor diffusion images with b = 0 and 100 s/mm
2
 1:05 
5 Tensor diffusion images with b = 0 and 300 s/mm
2
 1:05 
6 Tensor diffusion images with b = 0 and 600 s/mm
2
 1:05 
7 T2-weighted image 1:10 
8 Proton density images 0:25 
9 Dynamic T1-weighted images (DCEMRI) 21:00 
10 Proton density images 0:25 
 
Localization 
An axial fast gradient-echo sequence gave 3 dimensional images of the mice in the 
axial, coronal and sagittal directions. The acquisition was performed with an acquisition 
matrix of 256 x 128, 5 mm slice thickness and 2 mm slice gap. Illustration images in three 
dimensions are shown in Figure 3.8. 
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Figure 3.8. (a) Images of a mouse in the sagittal direction, (b) the axial direction and (c) a in 
the coronal direction. 
T2-weighted image 
Axial 2D T2-weighted images were obtained using a fast spin-echo sequence. These 
imageswere used to locate the slice with the largest tumor area, which are imaged in all 
subsequent acquisitions. The acquisition was performed with an acquisition matrix of 256 x 
256, TE/TR = 85 ms/4000 ms, 2 mm slice thickness, 2 mm interslice gap, bandwith (BW) of 
15.63 Hz, echo train length (ETL) of 16 and field of view (FOV) = 4 cm. 
Diffusion tensor images 
A single shot fast spin echo (SSFSE) sequence providing diffusion weighting in the 
direction of slice selection was used. This acquisition provided images without the significant 
degreeof spatial distortions that affect EPI-based diffusion imaging. The DTI-SSFSE 
sequence used in the experiments contained six gradient directions ([1 0 1], [-1 0 1], [0 1 1], 
[0 1 -1], [1 1 0] and [-1 1 0]) in addition to the zero gradient ([0 0 0]). This enabled 
calculation of the diffusion tensor and its eigenvalues, λ1, λ2 and λ3. The acquisition was 
performed with an acquistion matrix of 256x256, TE/TR = 78.7 ms/5000 ms, BW = 15.63 Hz, 
ETL = 16, 2 mm slice thickness, 1 mm interslice gap and FOV = 14 cm. DTI acquisitions 
were performed 4 times by using 4 combinations of b-values: 1) b1 = 0 s/mm
2
 and b2 = 50 
s/mm
2
; 2) b1 = 0 s/mm
2
 and b2 = 100 s/mm
2
; c) b1 = 0 s/mm
2
 and b2 = 300 s/mm
2
; and d) b1 = 
0 s/mm
2
 and b2 = 600 s/mm
2
. 
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T2-Weighted Image 
After the diffusion tensor imaging an addition axial 2D T2-weighted image serie was 
obtained using a fast spin-echo sequence with the same dimensions as the diffusion series 
(FOV = 14 cm), to be able to calculate ADC maps. The rest of theing parameters were 
identical to the first T2-serie in the exam. 
Proton density image 
Proton density images (TE = 4.4 ms, TR = 360 ms, image matrix = 256 x 128, FOV = 
6 cm, slice thickness = 1 mm, FA = 10°) were acquired of the tumors central slice prior to and 
after the dynamic contrast-enhanced imaging to determine the maximal signal intensity Smax  
DCEMRI acquisition 
DCEMRI was performed on the tumors central slice using a dynamic fast spoiled 
gradient-recalled (FSPGR) T1-weighted images (TE = 6.3 ms, TR = 120 ms, image matrix = 
256 × 128, FOV = 6 cm, slice thickness = 1 mm, flip angle (FA) = 80°). Following 
acquisition of 5 pre-contrast image data sets, the Gd-DTPA was manually injected during 3 
seconds. The dynamic imaging continued with 100 post-contrast images with a time 
resolution of 12 seconds, totally 20 min post-contrast imaging. The reconstructed voxel size 
of the T1-weighted images was 0.23 × 0.47 × 1 mm
3
. 
Sequence used for vascular input function determination 
The imaging slice was positioned in the center of left ventricle. The protocol was 
identical as for DCEMRI except for TR = 200 ms for the proton density images, and TR = 80 
ms, image matrix = 512 × 256 and slice thickness = 2 mm for the T1-weighted images, giving 
a voxel size of 0.11 × 0.23 × 2 mm
3
. The T1-weighted imaging consisted of 120 post-contrast 
images acquired every 10 seconds. 
3.6.3 DCEMRI analysis 
Acquired images were stored on the DICOM format and transferred to IDL 
(Interactive Data Language v6.2, Research Systems Inc., Boulder, CO) where all further 
analyses were performed using programs written in-house. Gd-DTPA concentrations were 
calculated from signal intensities and proton density images using the method of Hittmair et 
al (Hittmair et al 1994). They suggested using of a parameter called “enhancement factor”, 
EF, which can be determined as shown in equation 3.2. 
CconstR
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     (3.2) 
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where K is a flip angle correction factor listed in work of Hittmair et al (Hittmair et al 
1994), TR repetition time, Smax is maximal signal intensity, Snat is signal intensity prior the 
contrast administration, Spc is signal intensity after contrast administration, ΔR1 is changes in 
relaxation rate due to contrast agent administration, C is concentration of constart afent, const 
is proportionality constant.  
Maxiamal signal intensity Smax was determined from proton density images with low 
flip angle (FA=10°). Signal intensity on proton density images is dependent on proton density 
and flip angle as showed in equation 3.3 
sin)(  HNS          (3.3) 
where S is signal intensity, N(H) is proton density and α is a flip angle.  
Maxiaml signal intensity Smax for DCE-MRI sequence is determined by equation 3.4 


  80sin
10sin
1
80sin)( 10max SHNS      (3.4) 
To determine the proportionality constant const 2 reference phantoms one with water 
to simulate native tissue and another with water containeng 0.06M of Gd-DTPA to simulate 
contrast enhanced tissue. After calculation of EF according to equation 3.2, const can be as 
shown in equation 3.5 
C
EF
const            (3.5) 
where C is concentration of Gd-DTPA in the phantom. Concentration of contrast agent in 
mouse tissue Ct can be approximated as EF/const. 
From the mice subjected to left ventricle imaging, individual AIFs were determined 
fitting a biexponential function to the calculated Gd-DTPA plasma concentration curves as 
showen in equation 3.6: 
Cp(t) = A exp(-Bt) + C exp(-Dt)        (3.6) 
where A and B reflect the equilibration of Gd-DTPA between plasma and extracellular space, 
C and D represent the kidney clearance of Gd-DTPA and (A + C)
-1
 (l/kg) represents the 
plasma volume of the mouse per unit of body weight. The mean of the eight separate AIFs 
gave a single AIF with the following numerical constants: A = 3.57 ± 0.34 mM, B = 0.025 ± 
0.005 sec
-1
, C = 1.45 ± 0.15 mM, D = 0.0074 ± 0.0036 sec
-1
, which was assumed to be valid 
for all mice in the experiment. Using the AIF parameters and Gd-DTPA concentration versus 
time curves for each voxel within the tumor region-of-interest (ROI), each individual voxel 
was fitted to the Tofts and Kermode model (Tofts 1997) using equation 3.7: 
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where D is dose of GD-DTPA injected. It should be noted that Equation 3.7 assumes that 
plasma volume in tissue is 0 and do not contribute to overall enhancement.  
Applying equation 3.7 a voxel-wise estimations of the forward volume transfer 
constant for Gd-DTPA between blood plasma and the EES (K
trans
) (Tofts et al 1999), across 
the tumor was made. Unfitted voxels comprised those were the fit failed to converge due to 
low Gd-DTPA uptake or voxels giving values classified as nonphysiological (K
trans
 < 0, K
trans
 
> 0.01 sec
-1
). Unfitted voxels were normally in the center of the tumor, probably as a result of 
poor vascular supply in hypoxic or necrotic areas. On the basis of their low perfusion, the 
unfitted voxels were included in the K
trans
 maps as zeros, and therefore contributed in 
calculation of tumor mean K
trans
. The percentage of unfitted voxels, scored as the ratio of 
unfitted voxels versus the total number of voxels within the tumor ROI, was monitored for all 
tumors in the experiment.  
3.6.4 Diffusion analysis 
The obtained image data were transferred to a remote computer where quantitative 
diffusion measurements were obtained by calculation of ADC by using the software nICE 
(Nordic Ice Medical AS, Bergen, Norway). For the central slice of the tumor, ROIs were 
drawn on the T2-weighted images corresponding to trace-value maps. The ADC for each ROI 
was calculated automatically as (Mean ± SD). ADC for b value of 50, 100, 300 and 600 
s/mm
2
 were calculated relative to b=0 s/mm
2
 using equation 3.8: 
)ln(
1 0
bS
S
b
ADC           (3.8) 
where S0 is the signal intensity without diffusion weighting, and Sb is the signal intensity with 
diffusion gradient. 
3.7. Statistical analysis 
Statistical analysis was performed using SPSS 17.0 (SPSS, Cary, NC). One-Sample 
Kolmogorov-Smirnov Z test was used to test the assumption of normal distribution. For 
normal distributed data results were presented as the mean value and standard error of the 
mean (SEM) of each group. Pearson‟s correlation test was used to analyze whether 
correlations between variables were significant. All data were analyzed both by grouping all 
values within treatment groups (t-test) and by comparing mean individual animal data 
obtained pre- (day 0) and post-treatment (day 1 and day 9) (paired t-test), under conditions of 
normality. Data was presented in the form of mean and standard errors of the mean (SEM). 
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Chapter 4 
Results 
4.1 Animals used in experiment 
The total number of mice used in the experiment was 80. Only 73 of them developed a 
tumor suitable for the experiment. In table 4.1, the total number of mice included into the 
experiment, mice dead after castration, radiation treatment or under MRI procedure are 
presented. 
Table 4.1 Overview of the mice used in experiment. 
Group 
name 
Total 
numbe
r of 
mice 
Died 
after 
castratio
n 
Sacrificed 
because 
of failed 
regressio
n after 
castration 
Died 
after 
radiation 
treatmen
t 
Died 
during 
MRI 
acquisitio
n 
Sacrifice
d because 
of other 
health-
related 
reasons 
The 
number 
of mice 
used for 
data 
collectio
n 
CWR22 
control 
9 - - - 1 0 8 
CWR22 
irradiated 
9 - - 1 0 0 8 
CWR22C
A control 
55 9 10 
- 2 7 9 
CWR22C
A 
irradiated 
2 2 5 9 
Total 73 9 10 3 5 12 34 
 
4.2. Tumor growth 
Pretreatment tumor volumes of all tumors used in experiment were normally 
distributed (p = 0.71) with a mean tumor volume of 400 ± 37 mm
3
. 
Pretreatment tumor volumes for CWR22 group were normally distributed (p=0.39) 
with a mean tumor volume of 276±40 mm
3
. Figure 4.1 shows the growth curves for untreated 
and irradiated CWR22 tumors. Exponentially growing CWR22 control tumors reached 
endpoint of experiment in 28 days. The tumors in the CWR22 irradiated group showed a 31% 
volume decrease (p<0.01) as compared to pre-treatment volumes 24 hours after treatment, 
before a renewed growth was seen from day 1 to day 9. Then, the tumors started to regress, 
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and a lowest volume of 128±24 mm
3
 at day 41 was reached before a renewed growth 
appeared. At day 69, two tumors reached 16 mm in largest diameter and all animals in the 
group were sacrificed. The mean tumor volume of this group was 528±145 mm
3
 at the time of 
sacrifice. At day 23, the mean tumor volume of irradiated tumors was 5.3-fold less (p<0.01) 
than the mean tumor volume of CWR22 control tumors. 
 
Figure 4.1 Tumor volume (mean±SEM) for CWR22 control and CWR22 irradiated 
groups normalized to tumor volume at day 0. Radiation treatment was performed at day 0 
after an initial pre-treatment MRI. 
Pretreatment tumor volumes for CWR22CA group were normally distributed 
(p=0.643) with a mean tumor volume of 500±47 mm
3
. Figure 4.2 shows growth curves for 
CWR22CA tumors. Animals were castrated 32±3 days before the pre-treatment MRI. At the 
day of pretreatment MRI mice were randomized and separated into 2 groups, control and 
radiation treated. Mice in both groups reached experiment endpoint after 31±1 days after pre-
treatment MRI. Volumes of tumors in the CWR22CA groups decreased continuously as long 
as the experiment lasted. Tumors in CWR22CA control group showed insignificant decrease 
in tumor volume at days 4, 7 and 10  compared to pre-treatment values, while a 47% (p<0.01) 
and 41% (p<0.01) decrease in tumor volume was observed for days 26 and 30, respectively. 
No significant difference was observed comparing tumor volumes at day 26 and 30. 
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CWR22CA irradiated tumor showed a 34% decrease in tumor volume already at day 10 
(p=0.03), followed with a 61% decrease at day 20 (p<0.01), 70% at day 26 (p<0.01) and 67% 
at day 30 (p=0.01) compared to pre-treatment values. No significant difference between tumor 
volumes at day 20, 26 and 30 for CWR22CA irradiated group was observed. 
 
Figure 4.2 Tumor volume for CWR22CA control and CWR22CA irradiated groups 
normalized to the tumor volume at day 0. Radiation treatment was performed at day 0 after 
an initial pre-treatment MRI. 
4.3 Histology 
Figure 4.3 and 4.4 shows histological section of tumor tissue obtained after the mice 
were sacrificed at the end of the experiment. Macroscopic examination shows that CWR22 
control tumors are necrotic and heterogeneous, with necrotic areas localized over the whole 
tumor cross section. The tumors had clear zones of viable tumor cells (arrow 1, figure 4.3.a 
and b). It has an organization of a glandular tissue, forming layer structure around blood 
vessel, with a layer of elongated cells (arrow 2, figure 4.3.a and b). It has a shape of typical 
columnar epithelium with nucleus located in distal part of the cell, but no basal membrane is 
present. These structures are surrounded with human tumor cells (arrow 3, figure 4.3.b) with 
large nucleus. Parts of glandular tissue surrounded with connective tissue that consists of 
mouse cells (arrow 4, figure 4.3.a). 
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In figure 4.3.c and d, histological sections of tumor from CWR22 irradiated group are 
presented. Unlike CWR22 control tumors, no structural epithelial patterns were observed. 
Tissue consisted primary of human tumor cells with blood vessels and small fraction of 
connective tissue, primary muscle cells. Tumor cells seem to be smaller, mainly because a 
less cytoplasm volume having the same nucleus size. A large number of cavities can be 
noticed (figure 4.3.c, arrow 5). 
 
Figure 4.3 CWR22 control and irradiated group tumor sections died with hemaetoxilin and 
eosin. Panel a) and b) is CWR22 control group, magnification 10X and 40X respectively. 
Panel c) and d) is the CWR22 irradiated group. 
In figure 4.4 histological sections for the CWR22CA groups are presented. 
Macroscopically, tumors from both groups were flat, and more compact and solid. 
Histological sections of CWR22CA control showed that the tumors consisted mainly from 
human tumor cells (figure 4.4.a, arrow 1), but in comparison to CWR22 control group the 
cells were smaller. In addition to tumor cells a large fraction of mouse fibrosis cells were 
present (figure 4.4.a, arrow 2). On sections from CWR22CA irradiated tumors the cells were 
even more compact. A large fraction of mouse fibrosis cells were present (figure 4.4.c, arrow 
3). In figure 4.4.c multiple cavities can be seen (arrow 4), the same as in sections for tumors 
from CWR22 irradiated group. 
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Figure 4.4 CWR22CA control and irradiated group tumor sections died with hemaetoxilin 
and eosin. Panel a) and b) is tumor section for CWR22CA control group, magnification 10X 
and 40X respectively. Panel c) and d) for CWR22CA irradiated group. 
3.4. PSA analysis 
Mean pre-treatment concentration of total PSA in blood was 28.0 ± 2.1 ng/ml and 
16.2 ± 3.1 ng/ml for the animals bearing CWR22 and CWR22CA tumors respectively. For 
CWR22 control group total PSA concentration continued to increase along with tumor growth 
(day 1: 41,6 ± 6,9 ng/ml (p=0.12) day9: 88,2±12,2 ng/ml (p<0.01) end-point: 2124±13,8 
ng/ml (p<0.01)) (Figure 4.5), but total PSA blood concentration normalized for tumor volume 
showed no significant changes over time (Figure 4.7). For CWR22 irradiated group PSA 
concentration increased more slowly than for CWR22 control group (day 1: 44,1±8,3 ng/ml 
(p=0.06) day 9 48,4±9,7 ng/ml (p<0.01) end-point: 75,8±17,4 ng/ml (p<0.01)). Normalized 
PSA blood concentration showed an increase for two consecutive measurement days (145% 
(p<0.01) at day 1 and 112% (p<0.01) at day 9) compared to pretreatment values. At the last 
day of experiment for this group normalized PSA blood concentration was 87% higher 
(p=0.07) than pretreatment concentration. There was no significant difference in normalized 
total PSA concentration for CWR22 control and irradiated groups at the same experiment 
days.  
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In the animals bearing CWR22CA tumors the total PSA concentration was reduced in 
all subsequent measurement days compared to CWR22 groups. No significant difference was 
observed for both groups at day 0, 1 and 9 comparing within each group for consecutive days 
or between groups. The decrease in total PSA concentration from day 9 to the end-point of 
experiment was significant for both the control and the irradiation group (63% decrease, p < 
0.01 and 94 % decrease, p = 0.01, respectively) (Figure 4.6). 
 
Figure 4.6 PSA blood concentration(mean ± SEM)  for CWR22CA control and irradiated 
groups, ng/ml. 
There was no significant difference in total PSA concentration normalized to tumor volume 
for CWR22CA control and irradiated groups at day 1 and 9 compared to pretreatment values. 
At the last day of experiment a decrease of 55% (p=0.01) for CWR22CA control and 89% 
(p<0.01) for CWR22CA irradiated groups were observed compared to pretreatment values. 
Normalized PSA concentration for CWR22CA control group was 3.7-fold higher (p=0.04) 
than for the CWR22CA irradiated group. 
 
Figure 4.5 PSA blood concentration (mean ± SEM)  for CWR22 control and irradiated 
groups, ng/ml. 
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Figure 4.7 PSA blood concentration (mean ± SEM)  for all groups normalized to tumor 
volume, ng x ml
-1 
x mm
-3
 
Free PSA blood concentration was increasing for CWR22 control group from day 0 to 
the end of experiment, reaching a value 4.5 times higher (p=0.01) than pretreatment value. 
There were no significant changes for CWR22 irradiated group. For CWR22 control group 
compared to CWR22 irradiated group concentration was 1.73-fold higher at day 9 after 
irradiation (p=0.04) and 4.89-fold higher at the end of experiment (p=0.03). 
A 10% reduction at day 9 (p<0.01) and 64% reduction at the end of experiment 
(p<0.01) compared to pretreatment values was observed for CWR22CA control group. For 
CWR22CA irradiated group the reduction was 60% at day 9 (p<0.01) and 92% at the end of 
experiment (p<0.01) compared to pre-treatment values. Free PSA concentration was 4.3-fold 
higher (p=0.04) for CWR22CA control than irradiated groups at the end of experiment. Being 
the same for to pretreatment day and 24 hour after irradiation (p<0.01), free PSA 
concentration was higher for both CWR22 groups compared to CWR22CA groups (p<0.01) 
at day 9 and at the end of experiment. 
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The was no significant changes in the fraction of free PSA to total PSA for any group 
compared to pretreatment values or irradiated groups to control. Proportion of free PSA for 
CWR22CA groups was 1.5-3 times higher than for CWR22 groups, but the difference was not 
significant.  
There was a significant positive correlation (r=0.62, p<0.01 figure 3.10) between 
tumor volume and total PSA blood concentration. The correlation was stronger for animals 
with CWR22 tumors (r = 0.74, p < 0.01) than for animals with CWR22CA tumors (r = 0.27, p 
 
Figure 4.8 a) Free PSA blood concentration (mean ± SEM)  for CWR22 and CWR22CA 
control and irradiated groups, ng/ml. b) Free PSA blood concentration (mean ± SEM)  for 
CWR22 and CWR22CA control and irradiated groups normalized to tumor volume, ng x ml
-
1
 x mm
-3
. 
 
Figure 4.9 Proportion of free PSA versus total PSA (mean ± SEM)  for CWR22 and CWR22CA 
control and irradiated groups, ng/ml. 
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= 0.03). It was a linear dependence between total PSA blood concentration and tumor volume 
(r=0.39, p<0.01) (Figure 4.10). 
 
Figure 4.10. Correlation between total PSA concentration in blood (mean ± SEM) and tumor 
volume (mm
3
), all data used (r=0.62, p<0.01). 
When data from mice with untreated tumors only (non-castrated non-radiated mice) 
was used for analysis a significant strong positive correlation (r=0.73, p<0.01) between total 
PSA concentration and tumor volume were achieved (Figure 4.11).  
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Figure 4.11 Correlation between total PSA concentration in blood (mean ± SEM) and tumor 
volume (mm
3
), data from non-castrated control mice used (r=0.73, p<0.01). 
4.5. DCEMRI results 
4.5.1. Qualitative assessment of DCEMRI 
Using concentration uptake curves (Figure 4.15 and 4.17) obtained from each tumor 
voxel together with the VIF parameters, parametrical maps of K
trans 
(s
-1
) were generated using 
Tofts and Kermode modeling. A parametrical map is presented to the right along with 
respective post-contrast anatomical T1-weighted MR image (Figure 4.12). Manually selected 
ROIs (white line) showed on both MR image and on corresponding K
trans
 map. The dark blue 
areas within the tumor ROI on parametrical map are 0-value voxels. It is voxels which failed 
to fit with the model. The reason for it will be discussed in the discussion chapter. A color 
scale is presented to the left, with blue color equal to K
trans
 value of 0, dark red is the highest 
K
trans
.  
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Figure 4.12 A post-contrast anatomical T1-weighted MR image with manually marked ROI 
and a corresponding K
trans
 parametrical map for a mouse from CWR22 irradiated group (5) at 
day 9. The necrotic area (arrow 1) on the MR image corresponds to the unfitted area on the 
parametrical map (arrow 2). Water phantom (3) and phantom with water doped with GD-
DTPA (4) placed on 2 opposite sides of the tumor 
In figure 4.13. K
trans
 maps for 2 mice from CWR22 control and irradiated groups from 
day 0, day 1 and day 9 are presented. There was no significant difference in appearance of 
parametrical maps for CWR22 control group at day 0 and 1. Mean K
trans
 value were 
(0.036±0.001)x10
-3
s
-1
 and (0,035±0,001)x10
-3
s
-1
 respectively. There were almost no unfitted 
voxels, with the fraction of unfitted voxels being 4.3% and 1.5% respectively. On day 9 the 
fraction of unfitted voxels increased to 23.8%. The value of unfitted voxels was set to 0 and 
can be seen as dark blue areas on both K
trans
 and V
e
 maps.  
These changes can also be observed on concentration-time curves. Fast signal 
enhancement was observed in the T1-weighted MR images in the peripheral regions of the 
tumors, whereas signal enhancement in central regions was slower. The mean tumor contrast-
enhancement was starting to decrease for all tumors 20 min after Gd-DTPA injection, when 
the collection of dynamic data was stopped, but not down to pre-contrast values. 
The Tofts modeling of concentration – time curves for the same mouse as in figure 
4.13 are presented in figure 4.15. The curves have the same shape for day 0 and 1, before it 
changes at day 9. The initial increase in concentration is slower and wash out of the contrast 
agent is delayed. 
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Figure 4.13 Parametrical maps for a mouse from the CWR22 control group. Panels a, b and c 
shows K
trans
 maps, panel d, e and f shows Ve for days 0, 1 and 9, respectively. Maximum 
K
trans
 values represented by dark red color were 0.256x10
-3
s
-1
, 0.083x10
-3
s
-1
 and 0.055x10
-3
s
-1
 
for panel a, b and c respectively. Minimum K
trans
 value was 0s
-1
 and represented by dark blue 
color. Maximum values for Ve represented by dark red color were 8.46, 0.24 and 38.06 for d, 
e and f panels, respectively,  and minimum was 0 represented by dark blue color. 
In figure 4.14, parametrical maps for a mouse from CWR22 irradiated groups are 
presented. On both K
trans
 and Ve maps a difference can already be observed 24 hours after 
irradiation, with a formation of an area with low contrast uptake on days 9. Mean K
trans
 values 
decreased from (0.019±0.001) x10
-3
s
-1
 to (0.009±0.001) x10
-3
s
-1
, followed by an increase to 
(0.024±0.001) x10
-3
s
-1
. The fraction of unfitted voxels increased from 7% before radiation 
treatment to 41% 24 hours after radiation, before a 8.6 % decrease on day 9.  
Examining concentration-time curves (Figure 4.15) for the same mouse revealed 
changes in the curve shape already 24 hours after radiation treatment. Both the initial build-up 
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of contrast agent concentration and the wash-out was slower compared with the pretreatment 
curve.  
 
Figure 4.14 Parametrical maps for a mouse from CWR22 irradiated group. Panels a, b and c 
shows K
trans
 maps, panel d, e and f shows Ve for days 0, 1 and 9, respectively. Maximum 
K
trans
 values represented by dark red color were 0.052x10
-3
s
-1
, 0.041x10
-3
s
-1
 and 0.111x10
-3
s
-1
 
for panel a, b and c respectively. Minimum K
trans
 value was 0s
-1
 and represented by dark blue 
color. Maximum values for Ve represented by dark red color were 16.58, 20.44 and 5.69 for 
d, e and f panels, respectively,  and minimum was 0 represented by dark blue color. 
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Figure 4.15Tofts modeling of the mean concentration of Gd-DTPA in the tumor‟s central 
slice. Panel a represent the central slice of the tumor in mouse number 6 CWR22 control 
group, panels b – number 5 CWR22 irradiated group, days0, 1 and 9, respectively.  
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In Figure 4.16, parametrical maps of the central slice of a tumor from CWR22CA 
irradiated group are shown. The amount of unfitted voxels in the center of the tumor increased 
for 3 consecutive days. Mean K
trans
 values decreased from day 0 to day 9 (day 0: 0.0368x10
-3
 
s
-1
, day 1: 0.0293x10
-3
 s
-1
, day 9: 0.0124x10
-3
 s
-1
) while the fraction of unfitted voxels 
increased from 0.12% before irradiation to 16% 24 hours after, followed by a further increase 
to 66% at day 9. It was an increase in mean Ve from 0.04 at day 0 to 0.47 at day 1, followed 
by a decrease at day 9 to 0.05. 
 
Figure 4.16 Parametrical maps for a mouse from CWR22CA irradiated group. Panels a, b and 
c shows K
trans
 maps, panel d, e and f shows Ve for days 0,1 and 9, respectively. (IR5) 
Maximum K
trans
 values represented by dark red color were 0.113x10
-3
s
-1
, 0.144x10
-3
s
-1
 and 
0.146x10
-3
s
-1
 for panel a, b and c respectively. Minimum K
trans
 value was 0s
-1
 and represented 
by dark blue color. Maximum values for Ve represented by dark red color were 0.23, 1.19 and 
9.24 for d, e and f panels, respectively,  and minimum was 0 represented by dark blue color. 
The Tofts modeling of concentration – time curves for the same mouse are presented 
in Figure 4.17 along with concentration – time curves for a mouse from CWR22CA control 
group for comparison. There are no dramatic changes in curve shape as for tumors without 
androgen deprivation 24 hours after radiation treatment. Slightly delayed wash out can be 
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observed. But 9 days after treatment a slower Gd-DTPA concentration increase and almost 
absence of wash-out of contrast agent during acquisition time can be seen when comparing 
with pre-treatment curve (Figure 4.17.b). In contrast no change is observed in the shape of the 
Gd-DTPA concentration curves for the control mouse (Figure 4.17.a). 
 
Figure 4.17 Tofts modeling of the mean concentration of Gd-DTPA in the tumor‟s central 
slice. Panel a represent central slice of tumor in mouse number 4 CWR22CA control group, 
panels b – number 4 CWR22CA irradiated group, days 0, 1 and 9, respectively. 
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4.5.2. Quantitative results of DCEMRI 
Figure 4.18 shows mean K
trans
 values for all groups. On day 0 bars represent pre-
treatment groups of 16 CWR22 tumors and 16 CWR22CA tumors. Post-radiation, these 
groups are divided into four bars representing 8 tumors each. Mean pretreatment K
trans
 value 
for the CWR22CA group was 49% higher than for the CWR22 group (p < 0.01). At day 1 and 
9 the CWR22CA tumors showed no significant change in K
trans
 values post-irradiation or in 
control groups compared to pretreatment values. There was no significant difference between 
control and irradiated groups for CWR22CA tumors for all monitored days.  
For irradiated CWR22 tumors a 47% decrease (p=0.01) in K
trans
 value was observed 
on day 1 compared to pre-treatment values, followed by a 110% increase from day 1 to day 9 
(p< 0.01). Compared to CWR22 control tumors, CWR22 irradiated tumors had a smaller K
trans
 
value at day 1 (p=0.01) and day 9 (p=0.08). CWR22 control tumors showed no significant 
changes in K
trans
 values compared to pretreatment value.  
 
Figure 4.18 Mean ±SEM K
trans
 values (10
-3
 s
-1
) for CWR22 and CWR22CA control and 
irradiated groups on the MRI assessment days 0, 1 and 9. On day 0 pre-treatment CWR22 and 
CWR22CA groups represent 16 tumors each. On the post-treatment days 1 and 9 only control 
and irradiated groups are representing 8 tumors each. The tumors in the irradiation groups 
received a single fraction of 15 Gy after the day 0 MRI, followed by post-treatment MRI at 
day 1 (24 h) and day 9.  
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In figure 4.19, mean Ve for all the groups are shown. For CWR22 irradiated group a 
42% increase (p=0.03) was observed at day 9 compared to pretreatment values. No further 
significant differences were observed in control or irradiated groups compared to pretreatment 
values at day 1 and 9. 
For CWR22CA control and irradiated groups showed no significant difference 
whether when comparing to pretreatment value or control to irradiated groups for the same 
day after treatment.  
 
Figure 4.19 Mean ± SEM Ve for CWR22 and CWR22CA control and irradiated groups on 
the MRI assessment days 0, 1 and 9. On day 0 pre-treatment CWR22 and CWR22CA groups 
represented 16 tumors each. On the post-treatment days 1 and 9 control and radiation groups 
are represent 8 tumors each. The tumors in the irradiation groups received a single fraction of 
15 Gy after the day 0 MRI, followed by post-treatment MRI at day 1 (24 h) and day 9. 
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No significant difference in fraction of unfitted voxels was observed for the CWR22 
control group compared to pretreatment values. For the CWR22 irradiated group the fraction 
of unfitted voxels showed a 211% increase in the number of unfitted voxels (p=0.013) 
followed by a 57% decrease from day 1 to day 9 (p=0.032). No significant difference was 
observed for the CWR22CA control and irradiated groups compared to pretreatment values, 
between control and irradiated groups for the same day after treatment or comparing with 
respective fractions of unfitted voxels for CWR22 tumors. 
 
Figure 4.20 Fraction of unfitted voxels (percent) for CWR22 and CWR22CA control and 
irradiated groups on the MRI assessment days 0, 1 and 9. The tumors in the irradiation groups 
received a single fraction of 15 Gy after the day 0 MRI, followed by post-treatment MRI at 
day 1 (24 h) and day 9. 
The decrease in K
trans
 from day 0 to day 1 for CWR22 irradiated tumors coincided 
with a 212%  increase in the fraction of unfitted voxels, giving a significant negative 
correlation between K
trans
 and the fraction of unfitted voxels for this group (r = -0.69, p < 
0.01). K
trans
 was also negatively correlated to the fraction of unfitted voxels (r = -0.62, p < 
0.01) when values from all tumors at all time-points were included in the analyses (Figure 
4.21). 
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Figure 4.21 The correlation between the fraction of unfitted voxels (%) versus K
trans
 in the 
CWR22 model using all 4 treatment groups (r = -0.616, p < 0.01) (a). The correlation was 
stronger using only control tumors (r = -0.686, p < 0.01) (b). 
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4.6 DW-MRI results 
Using a b- value of 300 s/m
2
, theCWR22 irradiated group showed a 39% (p<0.01) and 
63% (p<0.01) increase in ADC at day 9 compared to pretreatment value and value at day 1, 
respectively. For b=600 s/m
2
 the increase was 35% (p=0.05) and 58% (p<0.01) (Figure 4.22). 
For both b-values at day 9 ADC for CWR22 irradiated group was 1.5-(p<0.01) and 1.6-fold 
(p<0.01) higher than for CWR22 control group (b=300 s/m
2 
and b=600 s/m
2
 respectively).For 
b=300 s/m
2
 at day 1 ADC for CWR22 control group was 1.2-fold higher (p=0.02) than for 
CWR22 irradiated group. There was no significant difference at b=600s/m
2
. 
 
Figure 4.22 ADC values for CWR22 control and irradiated groups normalized to day 0, b 
values 300s/m
2
 (a) and 600 s/m
2
 (b) 
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No significant changes in ADC values for CWR22CA control and irradiated groups 
were observed (Figure 4.23). Compared with non-castrated mice ADC for CWR22CA 
irradiated group was 1.5 (p=0.02) and 1.6-fold (p<0.01) less than for CWR22 irradiated group 
at day 9 (b=300 s/m
2
 and b=600 s/m
2
, respectively).  
 
Figure 4.23 ADC values for CWR22CA control and irradiated groups normalized to day 0, b 
values 300 s/m
2
 (a) and 600 s/m
2
 (b)  
There were no significant correlations for ADC values with total PSA concentration, 
tumor volume or ratio of unfitted voxels.  
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Chapter 5 
Discussion 
The goal of this project was to study the difference between prostate cancer CWR22 
xenografts with normal androgen supply and undergoing androgen deprivation treatment in 
immunedeficient mice by applying noninvasive visualization methods, like DCE-MRI and 
DW-MRI. The specific aim was to determine if tumor vasculature represented by K
trans
, 
fraction of EES represented by Ve and tissue structure represented by ADC in prostate cancer 
xenografts with full androgen supply will change following androgen deprivation, and if it 
will affect the radiation response. It was investigated whether the functional MRI methods 
gave more information about treatment response than classical clinical marker for prostate 
cancer, like PSA and tumor volume. 
5.1. Experimental Animals 
As other experimental models, subcutaneous xenografts in nude mice have their 
benefits and limitations. Xenografts derived directly from patient biopsies largely retain the 
morphological and molecular properties of the source tumors, and preserve the metabolic and 
growth patterns. But to be a sufficient model for research purposes it has to satisfy more 
demands. The tumor has to grow fast, linear or exponential with time, and have low necrotic 
fraction even with big volumes. The most important characteristics of xenografts for clinical 
experiments are relevance and opportunity to transfer results from animal to human. 
The CWR22 xenograft model is a prostate cancer model that satisfies most of the 
above discussed limitations. After it was established, it became a popular human xenograft for 
research groups working within prostate cancer. The reason for this is that it retains androgen 
dependency, regress when androgen treatment is used and relapses after a period of 3 to 10 
months (Nagabhushan et al 1996). Taking into account that the mice metabolism is 5 times 
faster than in humans (Hall and Giaccia 2006), it has a good correlation with relapse time 
point in patients, which is 2-5 years after androgen deprivation (Bruchovsky et al 1990, 
Trachtenberg 1987) The disadvantages of the CWR22 xenograft are uneven growth rate in 
different mice, even with equal testosterone levels, and a large necrotic fraction in large 
tumors, which is required for MRI of xenografts when using a clinical 1.5 T scanner. 
One of the challenges that influenced this work was the androgen-deprivation 
treatment. The treatment procedure was carried out by surgical castration. As it is impossible 
to provide personal care for each mouse after the surgery, 9 mice were lost due to prolapsed 
intestine. It also appeared that xenografts have to have a certain size to response to androgen 
deprivation. When xenografts were larger than 16 mm in largest diameter, they failed to 
regress and additionally 10 mice had to be sacrificed due to exceeding the upper limit for the 
size of the tumor. Androgen deprivation therapy also prolongs the time in the experiment for 
each mouse, which increase the probability for infections or physical damages that can lead to 
animal sacrifice. This led to the loss of 12 mice. At last, it should be noted that castration 
changes the metabolism of animals, making them weaker. In combination with radiation 
treatment it resulted in additionally 4 deaths. 
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During MR experiments the mice were anesthetized. When sleeping, the mice blood 
pressure and body temperature decreases. To maintain body temperature a heating system 
ensured equal conditions for all mice in the MRI experiment.  
5.2. The xenograft 
One of the standard instruments for tumor measurement is a slide caliper. CWR22 
xenografts are soft, and the thick skin of male mice compared to female, can reduce the 
accuracy of tumor volume measurement. In androgen-deprived mice, precise estimation of 
tumor volume can suffer from additional edema forming around the tumor due to the 
treatment. This leads to fluctuation in measurements for the same tumor. A large biological 
variation forces the use of more animals in each experiments group to obtain the necessary 
statistics in measured parameters, not only for tumor volume but also for other parameters. 
The large fraction of mice which died after androgen-deprivation treatment dramatically 
increased the number of animals involved in the experiment.  
Due to uneven growth and regress rate the process of randomization of mice into 
groups was complicated. One of the factors causing uneven take time and growth rate is 
heterogeneity in tissue samples obtained for inoculation. As it was said above, CWR22 
xenografts have a significant necrotic fraction. But in contrast to other xenografts that primary 
have a necrotic core in the center on the tumor, CWR22 xenografts have necrotic areas 
distributed all over the volume. This leads to heterogeneity in shape and quality of the 
implantation material. One of the solutions can be to inoculate xenografts in form of cell 
suspensions in a growth media, like Matrigel(tm). Another factor that can reduce 
heterogeneity in growth rate is to insert a time-release testosterone pellet at the time of tumor 
implantation to ensure constant testosterone levels during tumor growth, and then remove the 
pellet at the time of surgical castration. Implantation of testosterone pellets suppresses 
testosterone production by testicles and adrenals (Harkness et al 1975). This will lead to more 
even distribution of hormone levels between mice used in experiment. But as practice at our 
institute shows this do not have any significant benefits so far.  
Heterogeneity of the tumor and uneven distribution of necrotic areas can also 
compromise slice selection in MRI. As the tumor is implanted subcutaneously, the tumor can 
rotate and change slice position between acquisition days. This can lead to selection of 
different slices used for analysis with different tissue distribution and complicate data 
comparison between days. This problem will be discussed together with discussion of the 
MRI analysis. 
Mice were included into the experiment when tumor size reached 8 mm at the smallest 
diameter. Because tumors not grew evenly, the mice were included one by one or in small 
groups. Despite this, statistical analysis showed that tumor volumes were normally distributed 
and there was no significant difference between groups. For the CWR22CA group, with time 
from inoculation to castration being 25 to 56 days, inclusion was also complicated by uneven 
regress rate (time from castration until first MRI acquisition was 14 to 54 days). The total 
time from inoculation until the end of experiment varied from 84 to 125 days, with mean time 
for control group of 93±3 days and 106±5 days for the irradiated group. 
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Tumors used in the experiment were growing subcutaneously (s.c.), not orthotopic. 
Despite subcutaneous xenografts being a well established model, the use of an orthotopic 
model can be more preferable, especially in gene expression experiments, where 
microenvironment is important. However, it will not allow measurement of tumor volume by 
slide caliper. It is still possible to measure the size of orthotopic tumors using a three-
dimensional ultrasound micro-imaging technique (Kraaij et al 2002), but this technique was 
not available in this experiment. This fact and unclear benefits from using an orthotopic 
model for the experiment resulted in the choice of a non-orthotopic s.c. CWR22 xenograft. 
5.3 Histology 
On histological sections from CWR22 irradiated tumors acellular regions of various 
shape and size was seen. It is difficult to determine visually whether the empty spaces on the 
sections are of apoptotic genesis or if it is blood vessels. An experienced pathologist 
suggested that absence of blood and endothelial cells, ticked edge and high density could 
support an apoptotic nature of these cavities. On sections from CWR22 control tumors some 
acellular regions are also present. However, they are smaller, and the edge is smooth and have 
a round or oval shape. To exclude the possibility that it could be blood vessels an 
immunostaining using CD31 and anti-VEGF antibodies should have been performed.  
Tumors in the CWR22CA irradiated group showed larger decreases in tumor volume 
as a result of radiation treatment compared to the CWR22 control group, but the difference 
was not significant. On the histological sections obtained from tumors at day 30, the apoptotic 
acellular regions can be seen, while control tumors had compact packed cells without spaces. 
The pattern is similar to the one in CWR22 irradiated group tumors without androgen-
deprivation. But as only few samples were collected for the histology, no conclusion about 
significance of this finding can be made.  
5.4. PSA 
Total PSA concentration for the CWR22 control group increased with time on all 
consecutive measurement days, while there was no significant difference in PSA 
concentration normalized to tumor volume. This can be a result of constant leakage rate and 
the fraction of viable tissue in a tumor. It was found a strong linear correlation between total 
PSA concentration and tumor volume. This is consistent with earlier finding by other groups 
(Wainstein et al 1994). When data from mice with only untreated tumors was used in 
statistical analysis, the correlation was stronger. This suggests that the result of androgen 
deprivation or radiation on PSA and tumor volume appears on different time-points following 
treatment. have different timing. 
Radiation or androgen–deprivation treatment changes membrane permeability or even 
cell death that can affect leakage of PSA from cancer cells. Following radiation treatment, the 
PSA concentration increased 60% 24 hours after the procedure, but statistical analysis showed 
only close to significance level with p=0.06. There was no significant difference compared to 
the control group. This can be explained by biological variation between individual mice as a 
result of treatment. At day 9, a plateau can be observed, corresponding to the same plateau 
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showed by Dyke and colleagues (Dyke et al 2003) after a single radiation dose of 20 Gy. 
However, on their first measurement 6 days after treatment, when plateauing started, no 
significant difference from the control group was found. Only 11 days after treatment a 
significant difference between control and irradiated groups was achieved. In our experiment 
the first significant difference between control and irradiated groups appeared 9 days after 
irradiation. The low time-resolution is one of the major drawbacks of PSA as a marker for 
early treatment response since it takes time before the cells stop in the G1/G0-phase and they 
only proceed to apoptotic death when they fail to repair damages before the mitosis (Agus et 
al 1999). As it will be discussed later, K
trans
 values obtained from MRI examinations, showed 
response to treatment already 24 hours after treatment, thus K
trans
 potentially can be used as an 
early marker of treatment response.  
Comparing radiation treatment response with response to androgen deprivation 
therapy, some common features could be found. Earlier it has been shown that PSA has a 
half-life time of 3 to 8 days following mice castration and that PSA increased 3-fold 24 hours 
after treatment (Nagabhushan et al 1996). It was shown that initially the cells proceed to 
G1/G0 arrest instead of apoptotic death (Agus et al 1999). At the inclusion of animals into our 
experiment, the mean concentration of total PSA for the CWR22 groups was almost 2-fold 
higher than for CWR22CA groups that received androgen-deprivation therapy. Measurement 
of PSA concentration for the CWR22CA group was performed 14 to 54 (mean 32) days after 
androgen deprivation. This gives enough time for reduction of not only PSA concentration, 
but also slowing the metabolism of the cells as a result of PSA production. At the last day of 
the experiment (39 to 84 days, mean 63 days after castration) total PSA concentration was 
reduced to 5.29 ng/ml and 0.88 ng/ml for control and irradiated groups, respectively, which  
gives a 6-fold difference between the groups (p<0.01). It can be hypothesized that even it was 
no significant difference in tumor volume between the groups at the end of experiment, PSA 
concentration shows that combined androgen-deprivation and radiation therapy was more 
favorable than androgen-deprivation or radiation alone. As it was no MRI acquisition at this 
day, there is no data about physiological condition of the tumor to correlate with or support 
the hypothesis. Mean regrowth time for androgen-deprived tumors is 3 to 10 month. It can be 
suggested that this time will be longer for tumors that had a combination therapy. As the 
experiment was time-limited it was not possible to prove this hypothesis in practice for this 
experiment. However, by coincidence 4 mice that not was used in this experiment, but 
received the same treatment as CWR22CA irradiated group, showed no relapse 1 year after 
irradiation. 
Free PSA concentration is not a diagnostic parameter itself, but a low proportion of 
free PSA is associated with increased probability of finding prostate cancer by biopsy in 
humans. The proportion of free PSA was lower for the CWR22 groups compared to the 
CWR22CA groups, but the difference was not significant. It has been reported that in humans, 
free PSA has a half-life time of 110 minutes and therefore can be used as an early marker for 
treatment response, but no clinical recommendations or reference values have been 
established (Richordson et al 1996). Analyzing mean free PSA concentration values gave no 
significant difference in response to radiation or androgen deprivation compared to total PSA. 
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5.5. Radiation 
A single dose of radiation therapy was chosen for this experiment. A total dose of 15 
Gy was delivered in approximately 22 minutes. A high dose rate results in acute cell damage. 
Previously it has been reported metabolic changes in CWR22 tumors following a 20 Gy 
single dose x-rays radiation treatment (Dyke et al 2003). The dose distribution in the tumor 
volume should be equal. To compensate for the initial build-up of radiation deposition from 
the Co-60 source, a 5 mm thick bolus was used.  
In experiment design, single-dose radiation treatment has its advantages. The dose-
rate effect can be neglected, considering that delivery time is smaller than time needed for 
reparation and less than the cell cycle time, thus the radiation damage can be considered 
acute. As the CWR22 xenograft could be hypoxic, single dose radiation could allow 
maintaining a large fraction of cells due to its radioresistance. Following later reoxygenation a 
larger fraction of viable cells will be available and then the relapse will occur earlier than in 
fractionated radiation treatment. When using a fractionated treatment, multiple anesthesia on 
consecutive days will be needed, which could have increased the mortality of mice during the 
treatment procedure. 
5.6. MRI in cancer 
Development of new anti-cancer therapies requires optimization of existing treatment 
modalities and protocols to understand the regulation processes, therapy results and post-
therapeutic processes in individual tumors. A group of methods based on NMR are now being 
applied to both cell and animal models to assess tumor physiology and metabolism, which 
later can be available in clinical practice. Among other methods, MR spectroscopy, diffusion-
weighted MRI and contrast-enhanced MRI non-invasively provide information regarding 
tumor metabolism and pathophysiology. 
5.6.1 Dynamic contrast enhanced MRI. 
Introduction 
As any experimental method DCE MRI has its advantages and limitations. DCE MRI 
is a non-invasive and quantitative method that can be used in investigation of microvascular 
structure; it do not involve ionizing radiation and gives good spatial resolution. It also 
provides functional analysis by tracking the pharmacokinetics of injected low-molecular 
weight contrast agents as they pass through the tumor vasculature. It is sensitive to alterations 
in vascular permeability, extracellular extravascular and vascular volumes and in blood flow. 
One of the main apparatus advantages is that it can be performed on standard 1.5 Tesla 
clinical scanners. The popularity of DCE-MRI increases due to the fact that data obtained in 
the experiments can have direct clinical use. (O‟Connor et al 2007) A correlation between 
tissue MRI enhancement and immuno-histochemical microvessel density has been showed in 
many studies (Padhani 2003). 
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Analysis 
Different methods can be applied to analyze DCE-MRI data. Signal intensity 
enhancement on T1-weighted DCE-MRI images can be assessed in several ways, both 
qualitatively and quantitatively. Qualitative parameters of signal intensity-time such as shape, 
time to maximum enhancement or increase coefficient can be used for characterization of 
tissue and response to treatment. One of the disadvantages of this analysis is variation 
between acquisitions and individual examinations, making a direct comparison between 
animals or experiments difficult. Model free parameters describe tissue enhancement using 
descriptors such as initial and mean gradient of the rise of enhancement curves, maximum 
signal intensity, washout gradient and the area under gadolinium contrast concentration 
(AUGC). Such values have the advantage of being easy to calculate and can be used when 
quantitative techniques fail. Limitations are that they do not accurately reflect the contrast 
medium concentration in tissues and do not directly rely to tissue physiology (Alonzi et al 
2007). 
Converting the signal intensity into contrast agent concentration allows determination 
of parameters that are more physiologically related and independent of the way they were 
obtained. The relationship between signal intensity and contrast agent concentration is not 
linear (Tofts et al, 1999). It was showed by Hittmair and colleagues (Hittmair et al 1994) that 
a given contrast uptake causes an increase of relaxativity, which is independent of tissue or 
sequence parameters. However, signal intensity increase depends on native T1 relaxation time 
and native signal intensity, or in other words that the same uptake of contrast agent causes a 
higher increase of signal intensity in native hypointence tissues than in native hyperintence 
tissues. To determine the proportionality constant two water based phantoms, one with pure 
water, and one with water doped with Gd-DTPA of known concentration was used. As 
relative signal intensity increase depends on sequence parameters, like flip angle and TR, it 
complicates comparison between results with different sequence parameters. Hittmair and 
colleagues (Hittmair et al 1994)  suggested that under steady-state conditions with perfect 
spoiling of transverse magnetization and echo time much less than T2* relaxation time, the 
signal intensity is exponentially dependent of the T1 relaxativity. Using a parameter called 
enhancement factor, a differential T1 relaxation rate can be obtained from native and post-
contrast images. The enhancement factor is linear with contrast uptake and independent of 
other tissue and sequence parameters.  
To determine physiological characteristics such as flow and capillary endothelial 
permeability from contrast agent concentration data different pharmacokinetic models can be 
applied. The most common model parameters that are being used, like K
trans
 and Ve, are 
independent of acquisition protocol and do only reflect tissue characteristics. The advantage 
of these parameters is their universality. They are independent of image acquisition protocols 
and equipments (O‟Connor et al 2007, Leach et al, 2005). Another related parameter such as 
the rate constant Kep, which describes the ratio of K
trans
/Ve, was not presented in the results of 
this work as it do not carry additional physiological information. The Tofts and Kermode 
model was used to fit concentration-time curves. There are several models that can be applied 
to DCE-MRI data to enable calculation of K
trans
 and Ve, but many of them are similar to the 
Toft model (Larsson et al, 1990; Tofts and Kermode, 1991). These models make different 
assumptions. The Larson et al. model in a simple approach assumes that signal intensity is 
linearly related to contrast agent concentration and concentration increase is not flow limited. 
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As a result only the ratio of K
trans
/Ve can be found. The Brix et al model have a practical 
limitation demanding a long injection time, up to 4 minutes (Tofts 1997). The Tofts and 
Kermode model (Tofts and Kermode 1991) utilizes a bolus injection, a theoretical expression 
that only has concentration of contrast agent in tissue as an unknown, and fits well to gradient 
echo data from both human  tumors and transplanted tumors (Tofts 1997). As a result, 
independent K
trans
 and Ve parameters can be found. However, the use of K
trans
 as a measure of 
vascularization also assumes that blood flow is not limited and that flow is always greater 
than permeability (Tofts et al 1999/10). The Tofts and Kermode model assumes that the tissue 
blood volume negligibly contributes to the signal compared with that arising from the contrast 
agent in the interstitial space, and that the blood concentration of contrast agent is described 
by a time varying AIF. As a result, analyzes must be carried out carefully with special 
interpretation of data from large tumors with big necrotic areas or irradiated tumors. Using 
K
trans
 values from unfitted voxels that had a zero value takes this into account and results in 
reduced K
trans
. The model also assumes that contrast agent is mixed with plasma right after 
injection. In the experiment this assumption is reasonable as the blood circulation time in 
mice is short relative to the injection time. Taking into account the assumptions made by the 
model and for measurement of contrast agent concentration, quantitative kinetic parameters 
such as K
trans
 and Ve do allow comparisons between and within cohorts and different imaging 
centers (Tofts 1997) 
CWR22 tumors showed a 47% decrease in K
trans
 24 hours after a single radiation dose 
of 15 Gy. The specific contribution of radiation-influenced changes in flow, endothelial 
permeability and endothelial surface cannot be identified only from K
trans
 measurements. 
When irradiated, permeability of tumor capillary increases. Thus, K
trans
 becomes more flow 
dependent. A synergistic effect of perfusion, permeability and surface area on K
trans 
changes 
can be suggested. After irradiation, permeability of capillary membrane increased and a 
threshold was reached. No increase in Ve was seen for this group, suggesting that it is 
unlikely that the increase in permeability had a significant effect at this stage. K
trans
 can be 
considered perfusion-dependent. As a result of blood vessel damage or constriction of the 
capillary net, the endothelial surface cross-section is reduced. Decreased perfusion can be 
related to increased hypoxia and impaired nutrient supply. As it will be discussed later, an 
increase in the proportion of unfitted voxels 24 hours after treatment corresponds to decreased 
perfusion and formation of areas with acute hypoxia. The K
trans
 values in the unfitted voxels 
were set to 0 and used in calculation of means, which can explain the decreased K
trans
 values 
at day 1. As both Ve and tumor volume increased from day 1 to day 9, a formation of edema 
as a result of hypoxia and radiation damage can be suggested. As K
trans
 showed a 2-fold 
increase at day 9 compared to day 1 we can say that this increase could be explained by a 
combination of permeability and perfusion. 
CWR22CA tumors in castrated animals had 49 % higher mean K
trans
 than CWR22 
tumors in non-castrated animals. CWR22CA tumors were included in the experiment 32 ± 3 
days after castration of the animals. It has been reported earlier that 2 weeks after androgen 
withdrawal for androgen-dependent Shionogi tumor an increase in VEGF, possibly due to 
hypoxia (Jain et al 1998), leads to renewed blood vessel growth. It is not clear whether this 
result can be extrapolated to the CWR22 tumor to explain the increased K
trans
 values by 
increased vascularization. However, increased perfusion combined with increased 
permeability can explain these elevated K
trans
 values (Nicholson and Theodorescu 2004).. No 
significant changes in K
trans
 or Ve, as well as tumor volume or PSA, were observed in 
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CWR22CA tumors after radiation treatment. From previous studies it has been reported that 
androgen-deprived tumors are hypoxic, thus the absence of response can be explained by a 
hypoxic start of androgen-deprived CWR22CA tumors. It is known that hypoxic cells are 
more radioresistant due to absence of oxygen. Oxygen is “fixing” DNA radiation damages by 
interacting with DNA radicals and forming non-restorable damages that can lead to cell death. 
In absence of oxygen, cells are able to repair the damage and increase survival. It has been 
proposed that androgen deprivation induces acute hypoxia (Rothermurd et al 2005, 
Goonewardene et al 2002). Considering that tumor volume continues to regress due to cell 
death and that androgen withdrawal happened 32 days before the first MR acquisition, a 
chronic hypoxic state can be suggested. This controverts with earlier statements about 
increased vascularisation of CWR22CA tumors. The most reasonable explanation for 
radioresistant behavior of these tumors, supported by work of Agus and colleagues (Agus et al 
1999), is that most of the cells are in G0/G1 arrest. In the clinic, this lack of response to 
radiation treatment is observed in patients with prostate cancer following androgen-
deprivation therapy when an androgen-independent phenotype develops. The presence of 
hypoxia has been suggested to be an important factor in prostate cancer progression by 
protecting against tumor cell destruction (Marignol et al 2008). However, in the same work of 
Agus and colleagues it was shown that androgen-independent proliferation start 80 to 400 
days after androgen withdrawal. The latest inclusion of the tumor into our experiment was 54 
days after androgen deprivation and formation of the androgen-independent phenotype cannot 
be an explanation. Anyway, further investigations should be made, including verification of 
the radiation resistance of CWR22CA tumors after relapse.  
As significances were quite large and tumors in the same cohort were heterogeneous, 
the changes in K
trans
 may also represent different physiological processes in different 
individuals. Some tumors showed elevation and reduction in K
trans
 on day 1, with a shift to 
reduction and elevation respectively at day 9. These changes in K
trans
 could be a result of 
blood flow or permeability changes alone or a combination of both. Therefore, additional 
information is needed to correctly analyze DCE-MRI data, e.g. immunohistochemistry. A 
necrotic and hypoxic fraction and vascularization along with K
trans
 should be measured in 
order to understand the physiological mechanisms of this process. Unfortunately, this method 
will claim to sacrifice more animals at different time points to collect samples. As one of the 
principles of animal experiments is reduction of number of animals, it was not considered 
possible to do this in our experiment due to ethical and unclear benefits. 
Data analysis was performed on a defined region of interest that included all parts of 
the tumor. A highly enhanced strip between the skin and the tumor caused by edema or 
containing main blood vessels supplying the tumor and connective tissue was not included 
into measurement. Tofts and Kermode modeling was used to approximate experimental data 
in each voxel, fitting experimental concentration-time curve to a mathematical  model to 
obtain K
trans
 and Ve. Not every such experimental curve could be approximated correctly and 
they resulted in fit failures. When so, K
trans
 and Ve values for these voxels were set to 0 and 
included in calculation of mean tumor K
trans
 and Ve Previously it has been shown that the 
fraction of fit failures is strongly correlated to tumor necrosis (Bradley et al 2007). They 
showed that when excluding fit failures set to zero in calculation of mean tumor K
trans
, no 
correlation with tumor necrosis was found, but represents the K
trans
 values in perfused viable 
tissue. Both Bradley and colleagues (Bradley et al 2007) and Galbraith and colleagues 
(Galbraith et al 2003) proposed that the post-therapy non-enhanced voxels can represent areas 
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of tumor necrosis, supporting the inclusion of these voxels in mean K
trans
 calculation. In our 
experiment K
trans
 values were negatively correlated to the fraction of unfitted voxels, which 
can be attributed to treatment-induced increases in necrosis or tumor size-dependent increases 
in necrosis for untreated tumors. 
Imaging protocol 
Some models allow quantification of parameters such as flow, extraction fraction, Ve 
and mean capillary transit time (St Lawrence and Lee 1998). In the St. Lawrence and Lee 
model it is possible to separate perfusion and the permeability surface area product (PS). 
Recent experiments have showed that a temporal resolution of 1s is required to model the 
mean transit time accurately (Jayson et al, 2005; Parker and Buckley, 2005). In our 
experiment, acquisitions were made using a clinical scanner with a FSPGR sequence. The 
best time resolution with sufficient spatial resolution was 12 s. Choice of sequence for optimal 
image acquisition is always a trade-off between spatial resolution, temporal resolution and 
anatomical coverage. The fast T1-weighted spoiled gradient recalled echo sequence was used 
as it allows good contrast, medium sensitivity, high signal-to-noise ratio, adequate anatomical 
coverage and rapid data acquisition (Parker and Buckley, 2005). 
The choice of days for data acquisition was determined by previous experience and 
based on literature data. A time point 24 hours after irradiation was chosen as the most likely 
time-point to detect early radiation response. A time point 9 days after irradiation was enough 
to detect late response and recovery of tissue. The choice of this time point was also limited 
by exponentially growing control tumors, so that they would not be too large and develop 
necrotic cores that would have sabotaged the data.  
Arterial input function 
AIF reflects physiological parameters such as cardiac output, vascular tonus, kidney 
clearance and injection timing. Theoretically, both AIF and tumor contrast agent 
concentration versus time should have been measured directly for each examination. 
However, AIF measurements are technically demanding and in the best case it produces an 
indirect measurement from a nearby large artery that may differ from the vessel supplying the 
tumor (O‟Connor et al 2007). As a practical solution an idealized mathematical function can 
be used instead. This allows the experiment to be designed with a more freely choice of slice 
position, sequences and temporal resolution. The disadvantage of this approach is poor 
reflection of true blood supply (Parker and Buckley, 2005). 
In our experiment an alternative approach was used. AIF was measured for 8 mice of 
the same size and age as the mice used in experiment. It was mature male mice, weighing 30-
35 g. The calculated mean AIF of these 8 mice will not be fully true for mice receiving 
irradiation as weight and physiological conditions can change following treatment. Mice in 
the radiation groups lost some weight and looked more passive, which can correspond to 
decreased blood circulation. Castration also had an impact on mice weight and behavior. 
Despite the fact that AIF measurement has an impact on data analysis and that AIF can be 
defined for each group separately, the benefits of an increased number of mice used in the 
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experiment are not clear. The alteration in AIF coefficients were suggested insignificant and 
thus the same AIF were used for all animals. 
5.6.2 DW-MRI and ADC 
Introduction 
One of the approaches for characterization of tissue structure is to measure water 
diffusion in MR imaging. The practical breakthrough was made when Le Bihan in 1986 (Le 
Bihan et al 1986) and Moseley in 1990 (Moseley et al 1990) performed animal studies that 
demonstrated the value of DW-MRI for the early detection of stroke. Using diffusion tensor 
imaging, the directional dependence of molecular diffusion can be obtained. The main 
application of this method for cancer imaging is characterization of brain tumors, where ADC 
maps provide useful information regarding the architecture of the tissue (Charles-Edwards 
and deSouza 2006). Applications of DW-MRI over the past years include tissue 
characterization, monitoring of treatment response, diagnosing of acute ischemia, evaluation 
of brain tumors and detection of drug efficiency (Padhani et al 2009). In a recent report a 
promising role of DW-MRI in prostate cancer has been shown in detection, localization and 
assessment of prostate cancer aggressiveness and tumor staging. (Jacob et al 2008). 
Inside the cells all the processes occur in small compartments, separated with 
membranes. As a result, the mean path length is small and the contribution of intracellular 
water diffusion to signal reduction is low. The main part of signal reduction for different 
pathologies occurs due to water diffusion in the extracellular volume.   Larger and more 
compact packed cells in cancerous tissue lead to lower ADC values. The use of DW-MRI 
sequences can complement standard morphological MRI, MR spectroscopy and DCE-MRI 
and provide additional and supporting information in diagnosis of patients . It can be used for 
differentiation of highly cellular regions of tumors versus acellular regions and detection of 
treatment response (Charles-Edwards and deSouza 2006). 
Analysis 
As DW-MRI is a noninvasive approach, this technique can be used to monitor 
structural changes in tumor tissue for the same tumor over time. To obtain different diffusion 
weighting various b-values can be used. Low b-values (50 s/m
2
 and 100 s/m
2
) do not 
eliminate perfusion effects. Our results using these b-values gave no significant differences 
between the groups on the different days. The data we obtained from these acquisitions was of 
poor signal quality, arising due to technical issues with the scanner. Therefore, data from 
these b-values was not presented. In the result chapter, data for b=300 s/m
2 
and b=600 s/m
2
, 
when only free diffusion (Brownian displacement) and transmembrane transport contributes 
to signal decrease, was presented.  
As it was already discussed above, radiation treatment and androgen-deprivation 
therapy can result in changes of tissue structure and changes in water diffusion. In the 
experiment, significant changes in mean ADC values were observed only for CWR22 tumors 
in non-castrated mice after radiation treatment. An insignificant initial decrease in ADC was 
observed 24 hours after treatment compared to pre-treatment values, followed by a significant 
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increase at day 9 compared to day 1 and pre-treatment values. Ionizing radiation, causing 
endothelial apoptosis, leads to increase of vessel permeability for water. The resulting 
increase of the intracellular volume can be observed as a decreased ADC as compared to the 
pre-treatment values (Reide and Werner 2004). Rupture of cell membrane following radiation 
therapy can lead to membrane potential alteration, which is followed by failure of the Na-K-
ATPase pump and ion canals, and a cytotoxic edema will form due to a shift of water from the 
extracellular to intracellular compartments. This will result in decreased mean ADC values. 
As cells will fail to repair sublethal cell damage or have microenvironment and metabolite 
failures, the cells will proceed to death. Water mobility will increase and manifest as 
increased ADC values. This corresponds to the above mentioned increases in Ve and K
trans
 as 
well as tumor volume on day 1. It has been showed that a high tumor ADC correlates with a 
high necrotic fraction (Herneth et al 2003). Animal and clinical studies have showed that an 
increase in ADC values early after treatment initiation is associated with a subsequent 
reduction in tumor volume. Galons et al. (Galons et al 1999) demonstrated a clear, substantial, 
and early increase in the ADC after successful chemotherapy in breast cancer. One of the 
reasons why no significant changes in ADC was observed 24 hours after irradiation can be 
that the observed volume reduction might be a result of decreased cell volume and no 
formation of necrotic areas. An increase of ADC at day 9 corresponds with the increase of Ve, 
suggesting that it represents an increase in the extracellular volume. 
DW-MRI is being used to assess treatment response (Provenzale et al 2006, Manton et 
al 2006, Thoeny et al 2005). Mardor et al. in 2004 (Mardor et al 2004) demonstrated that pre-
treatment ADC values of primary and metastatic malignant brain lesions could predict 
response to radiotherapy treatment, i.e. tumors with higher ADCs responded less favorably. In 
patients with locally advanced rectal cancer, low mean pre-treatment tumor ADC predicted a 
larger percentage size change of tumors after chemotherapy (Dzik-Jurasz et al 2002). 
Quantitative DW-MRI has also been shown to have potential to predict response of colorectal 
hepatic metastases to chemotherapy, suggesting that a high pre-treatment ADC predicts for a 
poor response (Scurr et al 2006). The results of each of these studies are consistent with the 
hypothesis that a high ADC may be indicative of tumor necrosis and consequently greater 
resistance to treatment. There was no significant difference between ADC values of CWR22 
xenografts and androgen-deprived CWR22CA xenografts following radiation treatment. 
Moreover, no changes were observed in ADC between the control and radiationCWR22CA 
xenografts. Previously it has been suggested that tumors that receive androgen-deprivation 
treatment can be more hypoxic. But in our study, no samples were collected for histological 
staining to determine the necrotic fraction, cell density and size and compare with tumors with 
full testosterone supply.  
Imaging Protocol 
To obtain diffusion-weighted images a SSFSE-based DW-MRI sequence was used. It 
provides images without the significant degree of spatial distortions that single shot EPI 
sequences suffers from. EPI utilizes gradient rephasing, which results in spatial distortions 
from magnetic susceptibility effects, especially near air interfaces. In addition, EPI suffers 
from geometric image distortions created by significant eddy currents arising from the large 
magnetic field gradients used. For diffusion tensor imaging, encoding a minimum of six non-
collinear diffusion encoding directions are required to measure the full diffusion tensor. 
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A source of artifact in DW-MRI is different kind of motion not related to diffusion. 
Body motion due to breathing or internal organ movement can be an example. To reduce 
motion-related artifacts some precautions were taken. Mice were anaesthetized under the 
whole procedure and the tumor was implanted on the back in the pelvic region, so no organ 
movement or breathing motion could affect the tumor. The mouse was placed in a special 
constructed bed where it was fixed. But even if all motion artifacts are eliminated, the effects 
of capillary microcirculation could influence the measured ADC values. Reported ADCs for 
viable tissue have often higher values than expected, as a result of additional signal 
attenuation caused by perfusion (Harriet et al 2004). 
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Chapter 6 
Conclusion and suggestions for further work 
The goal of the project was to investigate whether non-invasive magnetic resonance 
imaging (MRI) methods can be used to obtain information about changes in structural and 
physiological conditions of prostate cancer xenografts before and after hormone- and 
radiation therapy treatment and if parameters such as K
trans
, Ve, fraction of unfitted voxels and 
ADC can monitor the treatment response. .  
In this project the following results were obtained: 
- CWR22 xenografts showed sensitivity to both radiation treatment and androgen 
deprivation, resulting in reduction of tumor volume. A strong correlation between 
tumor volume and prostate specific antigen were found, that correlated with earlier 
findings (Wainstein et al 1994). When data from mice with only untreated tumors was 
used in statistical analysis, the correlation was stronger. This suggests that the result of 
androgen deprivation or radiation on PSA and tumor volume appears on different 
time-points following treatment  
- Tumor regrowth after radiation treatment was observed, but due to limited 
experimental time no relapse after androgen deprivation was achieved 
- Ktrans showed an early decrease 24 hours after radiation treatment and fraction of 
unfitted voxels increase, while no changes in PSA were observed. It can be suggested 
that K
trans
 can be used as an early predictor parameter for treatment response. The 
specific contribution of radiation-influenced changes in flow, endothelial permeability 
and endothelial surface cannot be identified only from K
trans
. 
- Ktrans was negatively correlated with fraction of unfitted voxels, which can be 
attributed to treatment-induced increases in necrosis or tumor size-dependent increases 
in necrosis for untreated tumors 
- No early changes in apparent diffusion coefficient (ADC) were found. An increase of 
ADC 9 days after irradiation corresponds with the increase of Ve, K
trans
 and tumor 
volume, suggesting that it represents an increase in the extracellular volume. 
- Androgen deprived CWR22CA tumors had higher Ktrans values and lower PSA levels 
than the CWR22 tumors at the time of inclusion into experiment. No difference in 
ADC were observed comparing to pretreatment values  
- No significant changes in PSA, Ktrans, Ve, fraction of unfitted voxels and ADC were 
observed in the CWR22CA xenografts the first 9 days after treatment. A dramatic 
decrease in PSA in the irradiated CWR22CA xenografts at the last day of the 
experiment (62 days after castration) corresponds with earlier findings (Agus et al 
1999), where PSA levels for irradiated tumors has showed to be significantly lower 
than for untreated CWR22CA tumors. The absence of early response to radiation 
treatment can be suggested to be radiation resistance of CWR22CA. 
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It was shown that DCE-MRI, unlike DW-MRI, can be successfully applied for non-
invasive monitoring of treatment response in an experimental tumor model. The study 
suggests that K
trans
 can be used as an early predictor for radiation treatment response while 
mean ADC failed.  
As the experiment was conducted according to the rule of 3 R‟s (Replacement, 
Refinement and Reduction), the fewest possible number of mice were used. Due to high 
biological variation between xenografts and few mice in the experiment, one of the problems 
was to acquire enough data for statistical analyses. Considering this work as a pilot 
experiment further investigation should be done.  
Based on the results of this work, some suggestions for future experiments are:   
It was showed that 32 days after androgen deprivation the CWR22 tumor developed a 
radiation resistant phenotype. No significant changes in K
trans
, Ve or ADC, as well as tumor 
volume or PSA, were observed in CWR22CA tumors after radiation treatment. From previous 
studies it has been reported that androgen-deprived tumors are hypoxic, thus the absence of 
response can be explained by a hypoxic start of androgen-deprived CWR22CA tumors.  
Further investigations should be made, including verification of the radiation resistance of 
CWR22CA tumors after relapse. 
Post-radiation and post-castration changes in K
trans
 could be a result of blood flow or 
permeability changes alone or a combination of both. Therefore, additional information is 
needed to correctly analyze DCE-MRI data, e.g. immunohistochemistry. Immunohistological 
examination of histological sections using various antibodies can give information about cell 
density, apoptosis, necrosis, number of blood vessels, degree of blood flow and hypoxia. For 
quantification of hypoxia in tumors several exogenous markers can be applied, like 
pimonidazole, EF5 and CCI-103F (Ljungkvist et al 2007) that can capture normal conditions 
and treatment-related changes in hypoxia. A necrotic and hypoxic fraction and vascularization 
along with K
trans
 should be measured in order to understand the physiological mechanisms of 
K
trans
 changes and the role of hypoxia in this process. To correlate to ADC values, histological 
samples should be obtained for the same tumor at the same time point that MR acquisition is 
performed to determine the necrotic fraction, cell density and size and correlate these 
parameters with ADC values.  
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Chapter 8 
Appendix 1 
Based on some of the results from this thesis, a manuscript has been prepared for submission. 
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Abstract  
Purpose: Most prostate cancers (PCa) show initial favorable response following androgen-
deprivation therapy (ADT). Clinical evidence suggests that combining neoadjuvant or 
adjuvant ADT with radiation therapy improves local control and disease-free survival for PCa 
patients as compared to radiation therapy alone. We investigated whether tumor vasculature in 
androgen-sensitive CWR22 PCa xenografts is altered following ADT and whether ADT 
affects radiation response.  
Experimental design: Mice bearing androgen-sensitive CWR22 PCa xenografts were 
allocated into four groups receiving combinations of ADT by castration (CWR22c) and 
radiation delivered as a 15 Gy single dose at day 0. Non-invasive visualization of tumor 
vasculature by dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) was 
performed pre-radiation (day 0) and twice after radiation (days 1 and 9). The hemodynamic 
transfer constant K
trans
, reflecting vascular permeability, vascular surface area and flow, was 
calculated voxel-wise from DCE MRI.  
Results: K
trans
 of pre-radiation CWR22c tumors was 47 % higher than of pre-radiation 
CWR22 tumors (p = 0.01). Androgen-deprived CWR22c tumors showed no significant 
changes in K
trans
 following radiation, whereas K
trans
 in androgen-exposed tumors decreased 
from day 0 to day 1 (p = 0.04), followed by an increase from day 1 to day 9 (p = 0.01). There 
was a positive correlation between prostate specific antigen (PSA) and tumor volume (r = 
0.59, p < 0.01).  
Conclusions: Vascularization differs between androgen-exposed CWR22 xenografts and 
androgen-deprived CWR22c xenografts, with these two phenotypes also presenting different 
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radiation response. The study suggests serial monitoring of K
trans
 to be a useful indicator of 
therapy responses in PCa. 
 
Introduction 
Androgens are the primary regulators of prostate cancer (PCa) growth and proliferation (1). 
The effects of androgen-deprivation therapy (ADT) on prostatic carcinoma are significant, 
particularly for clinically localized disease. ADT results in cytological changes and a 
reduction in tumor cells due to a shift to quiescence and apoptosis (2, 3). Although ADT 
effectively causes dormancy and reduced tumor burden, complete eradication of PCa rarely 
occurs and biochemical progression in high-risk PCa patients receiving ADT is usually 
evident within 2 years. The mechanisms involved in the early transition from androgen-
sensitive to androgen-resistant PCa are not fully understood, with the androgen-resistant state 
remaining incurable.  
Dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) allows repeated, 
non-invasive visualization of tumor vasculature and has been suggested to become a tool in 
clinical response monitoring of increased and inhibited angiogenesis. Signal enhancement in 
DCE MRI is a function of microvessel density, vessel structure and rate of blood flow, and 
thus has the potential of assessing treatment-induced biological effects on tissue vasculature. 
Average tumor signal enhancement following contrast administration has been anticipated to 
decrease with increasing tumor volume due to insufficient vascular supply and development 
of regions of hypoxia and necrosis. However, studies have shown that tumor signal 
enhancement is independent of tumor volume (4, 5) and that DCE MRI provides 
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supplementary information of intratumoral conditions not available using standard, 
anatomical MRI.  
 Radiation therapy is an important treatment modality for PCa, although its efficacy 
decreases with increasingly advanced stage. Clinical trials have shown that combining 
neoadjuvant or adjuvant ADT with radiation therapy improves local control and disease-free 
survival for PCa patients as compared to radiation therapy alone, especially for high-risk 
patients (6, 7). Technological advances have brought intensity-modulated radiation therapy 
and high dose-rate brachytherapy into the clinic, allowing increased tumor doses while 
sparing normal tissues. These techniques require non-invasive imaging modalities, such as 
DCE MRI, for accurate localization of tumor masses. Radiation therapy failure includes 
extensive tumor masses, androgen-resistant metastatic disease and inherent radioresistance, 
warranting the use of DCE MRI to obtain information of vascular structure that can become 
useful in evaluation of radiation therapy response for PCa patients.  
In this study the contrast agent gadolinium diethylenetriamine pentaacetic acid 
(Gd-DTPA) was employed because of its wide availability and established clinical use. Using 
quantitative pharmacokinetic modeling of contrast agent uptake in a tissue of interest, 
vascular kinetic biomarkers associated with underlying physiological processes can be 
derived and used in monitoring response to treatments. The forward volume transfer constant 
between blood plasma and extravascular extracellular space (EES), K
trans
, has been shown to 
reflect acute treatment-induced changes in tumor vascularization (8). Although K
trans
 can be 
derived using a range of compartmental models, the model of Tofts and Kermode is the most 
commonly used both in clinical and preclinical models (8 - 10). The Tofts and Kermode 
model is based on contrast moving passively between two compartments, plasma and EES, 
and the transfer constant, K
trans
, between these two compartments, is dependent on a 
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combination of blood flow, vascular density, vascular surface area and permeability of the 
vasculature.  
The specific aims of the present study were to investigate if tumor vasculature in 
androgen-sensitive CWR22 PCa xenografts grown in mice is altered following ADT by 
castration and if ADT affects radiation response.  
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Materials and Methods 
Animals and xenografts 
Male, sexually mature BALB/c nude mice (25 – 35 g, 6 - 8 weeks old) were used in this 
study. The Institutional and National Committee on Research on Animal Care approved the 
protocol, and the experiment was performed according to Interdisciplinary Principles and 
Guidelines for the Use of Animals in Research, Marketing and Education (New York 
Academy of Science, New York, NY). The mice were bred at the animal department of our 
institute and kept under specific pathogen-free conditions at constant temperature (21.5 – 22.5 
°C) and humidity (50 – 60 %), and given sterilized food and water ad libitum.  
Xenografts were generated by subcutaneous (s.c.) implantation of (~2 mm)
3 
tumor 
tissue from the human androgen-sensitive CWR22 xenograft into one flank of each mice. 
Procedures for implantation, growth and harvesting of CWR22 xenografts in mice were as 
described in (11, 12). Animals with CWR22 xenografts were included into the experiment 
when their shortest tumor diameter reached 8 mm. Androgen-deprived CWR22 xenografts, 
denoted CWR22c, were obtained by castration of animals bearing CWR22 xenografts. The 
surgical castration was performed at a shortest tumor diameter of 13 mm, and the animals 
were included into the experiment when the CWR22c xenografts had regressed to a shortest 
tumor diameter of 8 mm. The time from castration to inclusion was 36 ± 4 days.  
Thirty-two animals were randomly allocated into 4 groups of 8 animals: CWR22 
control, CWR22 irradiation, CWR22c control and CWR22c irradiation. For the CWR22 
groups, all animals in the group were sacrificed when the longest tumor diameter of two of the 
tumors in the group reached 16 mm. Animals with CWR22c tumors were sacrificed 30 days 
after inclusion into the experiment. 
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To determine a mean vascular input function needed in pharmacokinetic modeling of 
contrast enhancement curves, eight separate male mice with identical weight and age as the 
other 32 animals were subjected to left ventricular DCE MRI examinations.  
Tumor tissue sections from control and 1 day post-radiation CWR22 xenografts (n = 
8) were used in immunohistochemistry to assess acute radiation-induced changes in tumor 
vascularization, perfusion and hypoxia.  
 
Tumor volume 
Tumor volumes were estimated using caliper measurements from implantation until the end 
of the experiment using the formula (length × length × width)/2, with length being the longest 
diameter across the tumor and width the corresponding perpendicular.  
 
Radiotherapy 
Tumors in the two radiation groups received a single dose of 15 Gy on day 0 (after pre-
radiation MRI) using a 
60
Co source (Mobaltron 80, TEM Instruments, Crawley, UK) with a 
dose rate of 0.8 Gy/min. Only the tumor was irradiated, while keeping the rest of the body 
outside the radiation field. A homogenous tumor dose deposition was achieved by placing a 5 
mm polystyrene bolus on top of the tumors to avoid the initial dose buildup from the cobalt 
source.  
 
Anesthesia and analgesia 
121 
 
Animals were anesthetized with s.c. injections of a mixture of 2.4 mg/ml tiletamine and 2.4 
mg/ml zolazepam (Zoletil vet, Virbac Laboratories, Carros, France), 3.8 mg/ml xylazine 
(Narcoxyl vet, Roche, Basel, Switzerland), and 0.1 mg/ml butorphanol (Torbugesic, Fort 
Dodge Laboratories, Fort Dodge, IA), diluted 1:5 in sterile water.  A dose of 50 µl/10 g of 
body weight was given prior to radiation, and 75 µl/10 g of body weight before MRI 
acquisitions and castration. Analgesia was provided to castrated animals by s.c. injections of 
buprenorphine (Temgesic; Schering-Plough, Brussels, Belgium) in a dose of 0.1 mg/kg.  
 
DCE MRI acquisition 
DCE MRI of the tumors‟ central slice was acquired at day 0 (prior to radiation), day 1 (24 h 
after radiation) and day 9 using a 1.5 T GE Signal LS clinical scanner (GE Medical Systems, 
Milwaukee, WI). Weight of individual animals determined the amount of contrast agent (Gd-
DTPA; Magnevist®, Schering, Berlin, Germany) diluted in heparinized saline to 0.06 M) to 
be administrated. Prior to MRI, a heparinized 24-gauge catheter attached to a cannula 
containing 0.01 ml g
-1
 body weight saline-diluted Gd-DTPA, was inserted into the tail vein. 
The animals were placed in a special cradle and put into an in-house built MR mouse coil (13) 
before the coil was placed in the scanner. The animals‟ temperature was maintained at 38°C 
during the acquisition.  
MRI included axial fast spin-echo T2-weighted images (TEeff = 85 ms; TR = 4000 ms; 
echo train length (ETL) = 16; image matrix = 256 × 256; field of view (FOV) = 4 cm; slice 
thickness = 2 mm) to localize tumor, and dynamic fast spoiled gradient-recalled (FSPGR) T1-
weighted images (TE = 6.3 ms, TR = 120 ms, image matrix = 256 × 128, FOV = 6 cm, slice 
thickness = 1 mm, flip angle (FA) = 80°) to investigate contrast kinetics. Following 5 pre-
122 
 
contrast images, Gd-DTPA was manually injected during 3 s before continuing dynamic post-
contrast imaging for 20 minutes with 12 s time resolution. Reconstructed voxel size of T1-
weighted images was 0.23 × 0.47 × 1 mm
3
. Corresponding proton density images (TE = 4.4 
ms, TR = 360 ms, image matrix = 256 x 128, FOV = 6 cm, slice thickness = 1 mm, FA = 10°) 
were acquired prior to and after DCE MRI.  
 Mean vascular input functions (VIFs) were obtained from DCE MRI of the left 
ventricle in eight separate male mice. The imaging protocol was identical to the one above 
except for TR = 200 ms for the proton density images, and TR = 80 ms, image matrix = 512 × 
256, and slice thickness = 2 mm for the T1-weighted images (voxel size 0.11 × 0.23 × 2 
mm
3
). T1-weighted imaging consisted of 120 post-contrast images acquired every 10 s. 
Acquired images were stored in DICOM format and transferred to a remote PC for further 
data analysis.    
 
DCE MRI analysis 
DCE MRI analysis was performed using in-house written programs in IDL (Interactive Data 
Language v6.2, Research Systems Inc., Boulder, CO). Gd-DTPA concentrations were 
calculated from signal intensities and proton density images using the method of Hittmair et 
al (14). Individual VIFs were determined by fitting a biexponential function to concentration 
curves from the left ventricle according to the following formula: 
VIF = A exp(-Bt) + C exp(-Dt)     (Eq. 1)  
with A and B representing equilibration of Gd-DTPA between plasma and extracellular space, 
C and D representing kidney clearance of Gd-DTPA and (A + C)
-1
 (l/kg) representing plasma 
volume of the mouse per unit of body weight. Mean VIF for the eight mice were found to be 
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characterized by the following constants: A = 3.57 ± 0.34 mM, B = 0.025 ± 0.005 s
-1
, C = 
1.45 ± 0.15 mM, D = 0.0074 ± 0.0036 s
-1
. This VIF was assumed to be valid for all mice in 
the experiment.  
 A region-of-interest (ROI) was manually delineated around the solid tumor in T1-
weighted images, excluding surrounding skin and connective tissue. Using the mean VIF 
parameters and contrast enhancement curves for individual voxels within the selected ROI, 
each voxel was fitted to the model of Tofts and Kermode (10). This allowed voxel-by-voxel 
estimations of the forward volume transfer constant for Gd-DTPA between blood plasma and 
the EES, K
trans
 (s
-1
) (8), across the tumor.  
Unfitted voxels represent voxels were the fit failed to converge due to low Gd-DTPA 
uptake or voxels with negative values (K
trans
 < 0). All unfitted voxels were set equal to 0 and 
included in K
trans
 maps and in calculation of mean tumor K
trans
. The fraction of unfitted voxels, 
scored as the sum of unfitted voxels versus the total number of voxels within the tumor ROI, 
was monitored. 
 
PSA 
Blood to PSA analysis were collected from the tail vein of each animal at days 0, 1 and 9 and 
at the time of sacrifice. Blood samples were allowed to coagulate before being centrifuged 
and frozen at -80°C until analysis. Free and total PSA were assayed using the 
fluoroimmunonometric AutoDELFIA ProStatus
TM
 PSA Free/Total kit (PerkinElmer Life and 
Analytical Sciences, Wallac Oy, Turku, Finland).  
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Immunohistochemistry 
Hypoxia was determined by injecting 80 mg/kg pimonidazole hydrochloride (1-[(2-hydroxy-
3-piperidinyl)propyl]-2-nitroimidazole hydrochloride, Natural Pharmaceuticals, International 
Inc., Research Triangle Park, NC, USA) in 0.5 ml saline intraperitoneally (i.p.) 60 min before 
sacrificing the animals. Five minutes prior to sacrifice, 15 mg/kg Hoechst 33342 (Sigma 
Chemical Co., St Louis, MO, USA) in 0.1 ml saline was injected i.v. for determination of 
tumor perfusion. Immediately after dissection, tumors were cut in two halves, frozen in liquid 
nitrogen and stored at -80°C until they were shipped to the Department of Radiation 
Oncology, Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands, for 
staining and imaging. 
 The central slice of the one half was cut before staining, and scanned according to 
procedures identical to as in (15) to obtain triple immunofluorescent images of tumor 
vasculature (9F1; TCL image, TNO, Delft, The Netherlands), perfusion (Hoechst) and 
hypoxia (pimonidazole). 
 
Statistical analysis 
Statistical analysis was performed using SPSS 16.0 (SPSS, Cary, NC). Differences between 
groups and time-points were analyzed using two-sided t-tests under conditions of normality. 
Pearson‟s correlation test analyzed whether correlations between variables were significant. 
Results are presented as mean ± standard error of the mean (SEM) and a significance level of 
5 % were used in all statistical analyses.  
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Results 
Tumor growth 
Pre-treatment tumor volumes were normally distributed (p = 0.60) with a mean tumor volume 
of 392.1 ± 37.7 mm
3
. Figure 1 shows normalized tumor volumes for control and irradiated 
CWR22 and CWR22c tumors.   
Exponentially growing CWR22 control tumors showed a 2.5-fold increase (p < 0.01) 
from day 0 to day 9. At the completion of the study (day 65), volumes of these tumors had 
increased 9.6-fold as compared to baseline. Radiation of CWR22 tumors induced an initial 
0.3-fold (p < 0.01) tumor volume regression at day 1, followed by 1.3-fold tumor re-growth at 
day 9. Irradiated CWR22 tumors showed growth inhibition before slowly relapsing from day 
51 and onwards. At day 30, mean normalized tumor volumes of irradiated CWR22 tumors 
were 12-fold less (p < 0.01) than tumor volumes of control CWR22.  
Volumes of tumors in the CWR22c cohorts decreased continuously as long as the 
experiment lasted. Thirty days after initiation of the study, volumes of control and irradiated 
tumors had decreased to 0.6-fold (p < 0.01) and 0.4-fold (p < 0.01) of pre-treatment values, 
respectively.  
 
PSA  
Figure 2a shows total PSA measured in the four groups at days 0, 1 and 9 and at the day of 
sacrifice. Mean pre-treatment total PSA was 30.7 ± 6.0 µg/ml for animals bearing CWR22 
tumors, whereas total PSA for castrated animals bearing CWR22c tumors was 18.3 ± 3.2 
µg/ml. For animals bearing control CWR22 tumors, total PSA increased to 88.2 ± 12.5 µg/ml 
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(p < 0.01) and 212.4 ± 13.8 µg/ml (p < 0.01) after 9 days and at the end of the experiment, 
respectively. For comparison, total PSA measured in animals with irradiated CWR22 tumors 
was 50.5 ± 10.7 µg/ml (p = 0.02) at day 9 and 75.8 ± 17.4 µg/ml (p = 0.02) at the completion 
of the experiment. In animals bearing CWR22c tumors, total PSA was reduced on all 
subsequent measurement days, with the decrease from day 9 to the end-point being significant 
for both control and irradiated animals (63.3 % decrease, p < 0.01 and 94.3 % decrease, p = 
0.01, respectively). There was a significant positive correlation between total PSA and tumor 
volume (r = 0.59, p < 0.01) (Figure 2b). The correlation was stronger for animals with 
CWR22 tumors (r = 0.74, p < 0.01) than for animals with CWR22c tumors (r = 0.27, p = 
0.03).  The correlation between total PSA and tumor volume was strong for both CWR22 and 
CWR22c tumors when only subjecting control tumors to analysis (r = 0.74, p < 0.01 and r = 
0.73, p < 0.01, respectively). 
 
Qualitative assessment of DCE MRI 
An example of an anatomical T1-weighted MR image through the centre of a tumor and 
matched slice of K
trans
 are shown in Figure 3a. The black areas within the tumor ROI are 
unfitted voxels. Rapid contrast enhancement was detected in the dynamic T1-weighted MR 
images in the peripheral regions of the tumors, whereas signal enhancement in central regions 
was slower. Within 20 minutes after contrast agent administration, wash-out of contrast agent 
was manifested for all tumors; however, pre-contrast signal intensity levels were not restored.   
 
Treatment monitoring using DCE MRI 
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Figure 4 summarizes mean tumor K
trans
 prior to treatment and 1 and 9 days post-radiation, for 
CWR22 and CWR22c tumors. Pre-treatment K
trans
 was 47.1 % higher for CWR22c tumors 
compared to CWR22 tumors (p = 0.01). Following radiation, K
trans 
of CWR22c tumors was 
unchanged when comparing with pre-treatment values. Furthermore, there were no significant 
differences in K
trans 
between irradiated and control CWR22c tumors at days 1 or 9. For 
irradiated CWR22 tumors, K
trans
 was reduced by 45.7 % from day 0 to day 1 (p = 0.04), 
followed by an 87.7 % increase from day 1 to day 9 (p = 0.01). No significant day-to-day 
variations were found for the CWR22 control tumors. Parametrical K
trans
 maps from day 0, 
day 1 and day 9 of an irradiated CWR22 tumor are shown in Figure 3b.  
The decrease in K
trans
 from day 0 to day 9 for control CWR22 tumors coincided with a 
38.6 % increase in the fraction of unfitted voxels, giving a significant negative correlation 
between K
trans
 and the fraction of unfitted voxels for this group (r = -0.79, p < 0.01). K
trans
 was 
also negatively correlated to the fraction of unfitted voxels (r = -0.61, p < 0.01) when values 
from all tumors at all time-points were included in the analyses (Figure 5). Table 1 shows the 
fraction of unfitted voxels within each group at the time-points for DCE MRI.  
 
Immunohistochemistry 
Figure 6 shows triple immunofluorescent images of tumor tissue sections obtained from 
control and irradiated CWR22 tumors. Qualitative analysis revealed different 
microenvironmental characteristics between the two groups. Control tumors were well-
vascularized with increased perfusion centrally, and hypoxia appeared equally distributed 
across the tumor. Radiation altered the vascular pattern, with large areas of hypoxia in the 
tumor core confining the vessels. 
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Discussion  
In the present study, we have shown that vascularization is different in androgen-sensitive 
CWR22 xenografts under androgen-exposed and androgen-deprived conditions and that the 
resulting PCa phenotypes have differential response to radiation.  
CWR22c tumors in castrated animals had 47.1 % higher mean K
trans
 than CWR22 
tumors in non-castrated animals. CWR22c tumors were included in the experiment 36 ± 4 
days after castration of the animals and increased vascularization following castration is 
consistent with findings in other studies demonstrating elevated VEGF expression, 
microvessel density and vascular permeability (1, 16), all attributes affecting the K
trans
 
measurement.  
CWR22 tumors showed a 45.7 % decrease in K
trans
 one day after receiving a single 
radiation dose of 15 Gy, which might result from radiation-induced reductions in blood flow, 
endothelial surface area, and/or vessel permeability. Together these factors contribute to 
compromised inflow of contrast agent, thereby leading to slowly- or non-enhancing regions in 
DCE MRI and reduced tumor K
trans
. We hypothesize that this decreased K
trans
 might be related 
to increased hypoxia, as immunohistochemical staining of tumor tissue sections showed 
increased areas of hypoxia in irradiated CWR22 tumors compared to the control counterpart. 
The irradiated tumors showed a more centrally distributed hypoxic pattern surrounding blood 
vessels, as opposed to the more peripheral and equally distributed hypoxia in the control 
tumor. Thus, the low K
trans
 values one day post-radiation might reflect reduced blood flow, 
and impaired oxygen- and nutrient supply corresponding to increased levels of hypoxia. 
Following radiation, no significant vascular changes were observed in CWR22c 
tumors. Such lack of response is also observed in PCa patients receiving radiation therapy 
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when the androgen-resistant phenotype develops. It has been proposed that ADT induces 
acute hypoxia (17, 18). Then, the radioresistant appearance of these tumors, as demonstrated 
by the persistently high K
trans
 values, could be the result of CWR22c tumors already being 
hypoxic at the time of radiation. Hypoxia creates a microenvironment in which tumor cells 
become less dependent on angiogenesis and more resistant to apoptosis (19), and the presence 
of hypoxia has been suggested to be an important factor in PCa progression by protecting 
against tumor cell eradication (20).  
In our study, fit failures were set to zero and included in calculation of mean tumor 
K
trans
. It has previously been shown that the fraction of fit failures is strongly correlated to 
tumor necrosis and, oppositely, that exclusion of fit failures from mean tumor K
trans
 
calculation eliminates this correlation (21). Thus, by excluding fit failures, the K
trans
 is 
essentially determined from the viable tumor rim, excluding necrotic hypoperfused cores 
resulting from successful treatments. Bradley et al (21) and Galbraith et al (22) proposed that 
these post-therapy low-enhanced voxels can be a useful non-invasive biomarker of tumor 
necrosis, providing support for including these voxels in our K
trans
 calculation.  
K
trans
 values were negatively correlated to the fraction of unfitted voxels, which can be 
attributed to treatment-induced increases in necrosis or tumor size-dependent increases in 
necrosis for untreated tumors, expelling well-vascularized tumor regions and reducing blood 
flow. The significant increase in the fraction of unfitted voxels in irradiated CWR22 tumors 
from day 0 to day 1 may also reflect elevated hypoxic fractions, as observed in the 
immunohistochemical stains. 
The model of Tofts and Kermode assumes the contrast agent to be instantly mixed in 
the plasma. In our experimental study, this assumption is reasonable as the blood circulation 
time in mice is short relative to the injection time. The use of K
trans
 as a measure of 
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vascularization also assumes that blood flow is not limited and that flow is always greater 
than permeability (8). Thus, especially for large tumors with necrotic cores or irradiated 
tumors, precaution should be taken when analyzing and interpreting results. However, much 
of the low flow areas in the center of the tumors were unfittable, and thus, this is taken into 
account by including these voxels in the mean tumor K
trans
 calculations.   
In this study we found that total PSA in CWR22 xenografts was positively correlated 
to tumor volumes. Furthermore, blood levels of PSA were decreasing following ADT. This is 
in accordance with findings from other groups using CWR22 xenografts in preclinical studies 
(11, 23). The use of functional imaging technologies, such as positron emission tomography 
(PET) and MRI, has revealed that changes in tumor biology and physiology precede changes 
in PSA. The rapid post-radiation decrease of K
trans
 in our CWR22 tumors was not coinciding 
with decreased PSA values, suggesting the possible utility of K
trans
 as an early predictor of 
treatment response. Rather than showing reduced PSA values, the CWR22 tumors 
demonstrated a slow increase after radiation. This has also been shown by others (23), and is 
explained by that an eventual transient decrease in PSA could have been missed due to low 
time-resolution of PSA measurements. However, the increase in K
trans
 of CWR22 tumors at 
day 9 fits with the increased PSA.  
The CWR22 xenograft model is derived from the primary tumor in a patient with 
metastatic PCa (11, 12, 24), providing a valuable model of the clinical situation of PCa since 
this xenograft regresses following ADT and shows stability before recurring growth in the 
androgen-resistant state is evidenced.  
Our interest in using DCE MRI to investigate the hemodynamic parameter K
trans
 was 
to make longitudinal, non-invasive measurements of tumor vascular characteristics following 
ADT by castration of the CWR22 PCa xenografts, which could preselect for differences in 
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radiation outcomes. This imaging modality enables repeated monitoring and hopefully 
prediction of ADT and radiation treatment responses, providing additional contributions 
towards individualized cancer therapy. Future investigations are warranted to expand the 
present preclinical study into more advanced stages of PCa following ADT, and also 
incorporate investigations of the role of hypoxia in the transition from androgen-sensitive to 
androgen-resistant disease.  
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Tables 
Table 1: Fraction of unfitted voxels from pharmacokinetic modeling 
 Day 0 Day 1 Day 9 
CWR22, C 17.5 ± 6.0 % 14.9 ± 4.4 % 24.2 ± 3.2 % 
CWR22, IR 12.6 ± 3.2 % *34.0 ± 7.2 % †17.1 ± 3.2 % 
CWR22c, C 16.9 ± 3.3 % 17.5 ± 3.1 % 19.7 ± 2.9 % 
CWR22c, IR 13.4 ± 5.8 % 14.7 ± 6.0 % 25.5 ± 7.8 % 
The fraction of unfitted voxels from Tofts and Kermode pharmacokinetic modeling of DCE 
MRI data for each group on the three imaging time-points. *The increase in the fraction of 
unfitted voxels from day 0 to day 1 in irradiated CWR22 tumors was significant (p = 0.02). 
†The increase in the fraction of unfitted voxels from day 1 to day 9 in irradiated CWR22 
tumors was close to significant (p = 0.06). C = control tumors, IR = irradiated tumors 
receiving a single fraction of 15 Gy after the MRI at day 0, and 24 h before the MRI at day 1.   
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Figures 
 
Figure 1: Tumor volumes of CWR22 and CWR22c normalized to day 0 (day of inclusion). 
Days for MRI are indicated by arrows. Each time-point represents normalized mean and SEM 
values. C = control tumors, IR = irradiated tumors receiving a single fraction of 15 Gy after 
the MRI at day 0.  
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Figure 2: Total PSA in blood (mean ± SEM) at days 0, 1, 9 and the end of the experiment for 
the four treatment groups (a). C = control tumors, IR = irradiated tumors receiving a single 
fraction of 15 Gy after the MRI at day 0. Total PSA in blood versus tumor volume (r = 0.59, p 
< 0.01) (b).  
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Figure 3: Anatomical T1-weighted image through the centre of a CWR22 tumor with 
illustration of the delineation of tumor ROI, and the corresponding K
trans 
(× 10
-3
 s
-1
) 
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parametrical map within the selected ROI. The black areas within the tumor ROI are unfitted 
voxels (a). K
trans 
(× 10
-3
 s
-1
) maps and mean values of a CWR22 tumor pre-radiation (day 0) 
and post-radiation (day 1 and day 9) (b).  
 
Figure 4: K
trans
 (mean ± SEM) values pre-radiation (day 0) and 1 and 9 days post-radiation. 
Bars on day 0 represent pre-treatment groups for 16 CWR22 tumors and 16 CWR22c tumors. 
Post-radiation, these groups are divided into four bars representing 8 tumors each. C = control 
tumors, IR = irradiated tumors receiving a single fraction of 15 Gy after the MRI at day 0.   
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Figure 5: Correlation between the fraction of unfitted voxels and mean K
trans
 using all four 
treatment groups at all time-points (r = -0.61, p < 0.01).  
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Figure 6: Triple immunofluorescent images showing vascular architecture (9F1, red), 
perfused vessels (Hoechst 33342, blue) and hypoxic areas (pimonidazole, green) in control (a) 
and 1 day post-radiation (b) CWR22 tumors.  
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